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1. Introduction
This dissertation will examine the potential for using health claims databases in the 
economic evaluation of medicines. We examine the background and development of 
these ‘new’ sources of information and, taking a case study for a particular disease area, 
give an example of how the data can be used to perform an initial economic evaluation 
and inform the types of decisions health economists in the pharmaceutical industry 
routinely take.
1.1 The use of health economics in the pharmaceutical industry
In the face of steadily rising healthcare costs, countries throughout the world are 
struggling to reform their healthcare systems. Many of the reforms aim to control the use 
of technology either by limiting access or indirectly controlling prices. Despite being a 
small fraction of all healthcare spending, pharmaceuticals have not escaped the scrutiny 
of these reform efforts. Many governments see tlie rising price of diugs as a major 
problem, especially since the elderly population, which is increasing, represents the 
largest population segment for pharmaceutical consumption. World-wide efforts to 
control healthcare costs have led to an examination of the allocation of resources, with a 
focus on demonstrating cost-effectiveness as well as therapeutic value. To succeed, new 
drugs increasingly have to demonstrate they represent a more efficient use of scarce 
healthcaie resources.
14
The randomised controlled tidal has traditionally been employed as the vehicle for 
measuring treatment effects and are now routinely used to collect ‘piggy-back’ health 
economic data in order to display a product’s ‘value’. The justification for this lies in the 
fact that phase IE trials, in particular, provide an opportunity for generating an early 
economic profile of a specific medicine. While being a valid ar gument, the issue remains 
that the RCT is necessarily concerned with internal validity (isolating the relationship 
between the cause and effect of a medicine) than external validity (generalisability to the 
wider population). The societal and population perspective, traditionally adopted by 
health economics, makes the latter aspect the most relevant and increases the need to 
identify data sources and methods that will allow generalisability to be improved. One 
such avenue may be the numerous healtii insurance claims databases found in the US.
1.2 The development o f managed care, HMOs, PBMs and insurance databases
In the broadest sense of the phrase, managed care can embrace any form of monitoring or 
control of healthcare provision and/or financing which leads to action being taken to 
improve the situation. It is generally understood that ‘improving the situation’ means 
improvements from the payers point of view i.e. getting the same or better healthcare for 
reduced costs, better value for money (Rubens 1984). However, it is not uncommon for 
the phrase ‘managed care’ to be associated only with specEic parts of the healthcare 
system. In pairicular, managed care is frequently taken to mean Health Maintenance 
Organisations (HMOs) and Preferred Provider Organisations (PPOs), which play a
15
prominent role in controlling costs, or to refer to specific tolls used by managed care 
operators such as formularies and drug utilisation reviews.
The definition given to managed care depends to a lai'ge extent upon the context and 
standpoint from which it is given. Therefore, as is to be expected from such a wide 
subject area opinions vary as to it’s precise meaning.
Managed care is a phenomenon that is cuirently unique to the United States. Managed 
care covers all forms of healthcare provision in which some attempt is made to control 
the costs incurred, in contrast to indemnity insurance which has traditionally left the 
choice of healthcare to the individual and reimbursed claims for any treatment covered by 
that individual’s insurance policy without involving providers or questioning the cost.
The wave of growth of managed care organisations in the US began at the beginning of 
the 1980s when escalating healthcare costs first caused employers to look seriously at 
alternative means of financing their employees healthcare. The number of plans offered 
began to escalate in line with the employers demands resulting in the development of a 
number of variations of managed care, each placing emphasis on a different aspect of the 
healthcare chain (Hudson 1989). For example, some plans emphasise the cost of 
healthcare per se, while others stress the importance of retaining customer choice or of 
the role played by preventative medicine in effective use of healthcare facilities. Hudson 
(1989) believes the three key reasons behind the successful growth of the managed care
16
sector in the last decade, and the evolution of healthcare plans into the form now familiar 
in US today are that:
1. many consumers and payers have been forced to put economic considerations ahead of 
freedom of choice as healthcare costs escalate.
2. in line with this switch in priorities, the medical profession has seen a decline in it’s 
political and economic power and, as a result, has had to become more flexible in the 
services it provides.
3. the existence of a large number of newly qualified doctors has made recruiting of 
physicians by managed care organisations much easier, encouraging new start ups which 
would not previously feasible.
Managed care operates on a regional basis across the US which has led to the emergence 
of a very large number of managed care plans being offered to consumers in total. Most 
plans cover a well-defined geographical area, frequently centred on one city and rarely 
crossing state borders. However, the number of companies operating these numerous 
plans is comparatively small. Most operators offer a wide range of plans, either covering 
a number of geographic regions, or giving consumers within one or two areas a greater 
choice of the type of healthcare plan they opt for. This situation has arisen around the 
demands of employers who are the principal customers of managed care companies. In 
line with the switch in employers attention from traditional indemnity insurance to other
17
more effective means of healthcare financing, two important requirements which had to 
be accommodated were (Johnson 1991):
1. their desire to offer employees a choice of healthcaie plan without needing to deal with 
a large number of managed car e operators to achieve this, and
2. the need for large employers to offer cover to workers in many states, again without 
needing to deal with too many separate operators.
The companies now fulfilling these needs have origins in three sectors of the economy. 
Firstly, traditional indemnity insurers have adapted die services they offer to encompass 
managed care plans as a means of holding on top their existing customer base; secondly, 
the hospital sector has taken an active role in developing managed care, also as a means 
of competing for customers as consumers and payers become more demanding and 
discerning; and, thirdly, many new operators have entered the managed care arena 
attracted by the business opportunities becoming available in a traditionally non­
competitive environment and by the support given to this type of healthcare provision by 
successive US governments. The diversity is illustrated by the composition of the top 10 
players in the managed care industry in the US in 1993:
1. Kaiser Foundation Health Plans Inc. Private non-profit HMO, 12 plans offered.
2. Blue Cross and Blue Shield System. Non-profit insurance, 76 plans offered.
3. US Healthcare Inc.. Public, for profit HMO, 8 plans offered.
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4. Prudential Health Care hic. Mutual, for profit insurance, 29 plans offered.
5. CIGNA Healthcare Plans Inc. For-profit insurance, 45 plans offered.
6. United Healthcare Coi*p.. Public, for profit HMO, 18 plans offered.
7. Health insurance Plan of NY. Private, non-profit HMO, 3 plans offered.
8. Aetna Health Plans. For profit insurance, 25 plans offered.
9. Humana Inc. Investor owned healthcare company, 18 plans offered
10. PacificCai'e Health Systems Inc. Public, for profit HMO, 5 plans offered. 
(Pharmamarkets report, 1991)
Characteristics common to a large number of managed care operators include the 
following:
1. operation on a state by state basis with marketing, finance, recruitment, etc. being 
undertaken centrally and the actual healthcare plans managed locally.
2. subsidiaries of one company will offer between them a variety of plans from indemnity 
insurance to HMOs and PPOs across a number of geographic areas.
3. customers are usually employers with contact with the general public.
4. separate HMOs, PPOs etc., have evolved to offer managed care plans to Medicare 
patients.
5. organisations frequently run by business professionals with no medical training.
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6. centred ai'ound populated areas where there are sufficient healthcare providers for 
competition to exist and for contracts to be drawn up with a number of providers without 
limiting competition and shutting out individuals who do not subscribe to a specific plan.
7. operators have access to lar ge amounts of healthcare outcomes and resource utilisation 
data.
Beyond these general characteristics, managed care plans and the companies operating 
them vary enormously depending upon the type of plan in question, it is important to 
understand the principal types of managed care plan offered and the characteristics of 
each in order to understand the US managed car'e market and resulting claims databases.
1.2.1 Health Maintenance Organisations (HMOs)
HMOs are currently the most popular type of managed care in the US and are second 
overall after traditional indemnity insurance plans (Promark report 1991). There were 575 
HMOs in existence by the end of 1992 covering approximately 41.1 million lives or 16% 
of the US population. They also accounted for half of all plans offered by employers to 
their workforce.
Most HMOs encompass the following criteria in the administration of their plans
1. use of cost conscious providers
2. use of monitoring data to record healthcare utilisation
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3. requirement that providers accept a shaie of the financial risk involved in healthcare 
provision (usually incorporating capitation agreements).
4. HMO must generate a significant proportion of each providers business if the plan is to 
effectively influence his prescribing habits.
5. the greater the market share held by an HMO the greater will be that plans ability to 
recruit new providers to its network.
There are five basic models of HMO distinguished primaiily by the relationship between 
the HMO and the participating physicians (Healthscope report 1998). They aie:
1. Staff Model HMO
The HMO employs all the physicians and providers who provide care for plan members 
and invests its own capital in provision of healthcare facilities in which the physicians 
operate. Practitioners receive an annual salary plus performance related bonus paid by the 
HMO and are limited to treating patients enrolled with their HMO.
2. Individual Practice Model
The HMO negotiates contracts with individual physicians over a wide geographic area; 
these physicians are not employed by the HMO and treat patients in their own 
independent surgeries. Payment is normally on a fee for service basis for each plan 
member treated or sometimes fee per patient; physicians can sign contracts with as many 
HMOs as they please.
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3. IPA Model HMO
Independent Practice Association model. This is very similar to the Individual Practice 
Model with the exception that the HMO negotiates contracts with associations 
representing individual practices, who in turn negotiate contracts with their individual 
physician members. As above, payment is on a fee for service basis; physicians in this 
model are free to sign contracts with as many different HMOs as they please.
4. Group Model HMO
The HMO negotiates a contract with one large multi-speciality medical group practice 
which must accept provider risk sharing via payment of a capitated monthly fee (i.e. fixed 
monthly fee for each HMO enrolee regardless of the treatment actually given). Physicians 
can work for more than HMO.
5. This is the same as Group model HMO with the exception that the HMO contracts with 
a number of group practices rather than one large medical provider conglomerate. 
Payment is still on a capitated basis. Physicians can work for more than one HMO.
A survey carried out by the Congressional Budget Office (1992) calculated that HMOs 
reduce healthcare usage by 7% compared to unmanaged care and by 4% to fee for service 
care (which is categorised as partially managed care since many fee for service physicians 
make use of certain features of managed car e such as utilisation reviews, to improve the 
efficiency of their practices). However, this improvement only applies to staff model
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HMO. IPA model plans appear to achieve savings of only 3% and 1% respectively over 
unmanaged and fee for service care.
Staff model costs have been proven to be the most effective in controlling healthcai'e 
costs due to certain features (Promai'k 1991) inherent in their structure which enables the 
operating company to keep tighter control of the activities of healthcare providers as well 
as members. Such features that are unique to staff based models are:
- the ability to regulate die supply of physicians and hospital beds according to the size of 
the population served (achievable since healthcar e providers are employees of the 
managed care company and company’s own capital is invested in the provision of 
healthcare facilities).
- enforcement of the HMO’s formulary is easier as all prescribers are employed by the 
HMO.
- physicians loyal to one plan have an incentive to follow more efficient prescribing 
practices since they will reap the benefits themselves in the form of bonus payments and 
lower premiums offered leading to a larger client base; in the same way, plan managers 
have an incentive to devise more efficient prescribing patterns will not be passed on to 
competitors as is frequently the case with more open models.
However, from the consumer’s point of view the feature of HMOs which distinguishes 
them from other forms of managed care is the restrictions they place on consumer choice. 
In general, upon joining an HMO plan, consumers agree to obtain all their healthcare 
from physicians, hospital and specialists affiliated to that particular plan. Physicians are
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seen as gatekeepers since access to other healthcare providers can occur only on their 
recommendation.
From a consumer’s perspective, within the HMO sector there is a choice between two 
types of plan (Lowe 1992). The first is a fully insured plan which offers comprehensive 
medical coverage in exchange for a fixed monthly premium set in advance and not related 
to the amount of care actually used. Lower premiums can often be obtained in exchange 
for acceptance of a higher co-payment rate in the event of care being required. Hospital 
care requires a referral from die piimai'y care physician chosen by the enrolled member, 
except in emergency cases and is also caiiied out in hospitals contracted to work for the 
HMO in question.
The second is an out of network plan (or open ended plan). This is a hybrid plan which 
combines the freedom of choice available through traditional fee for service indemnity 
insurance with the cost control of HMOs and operates in the same way as a fully insured 
plan but with the option to choose hospital and specialist care from providers outside the 
HMOs contracted network.
i.2.2 Preferred Provider Organisations (PPOs)
PPOs are the second most popular fomi of managed care after HMOs. They have been 
described as “remnants of the fee for service world” since they do not have the authority 
to accept financial risk for healthcare provision and do not have their own network of
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physicians. Rather they collect an administrative fee to act as go between for consumers 
and healthcaie providers. Physicians are paid according to a negotiated fee schedule for 
each patient treated, not on a capitated basis.
Providers agree a discount with PPO administrators in return for which PPOs will 
encourage their members to use these physicians. This is achieved by offering better 
premiums and/or lower co-payments to those consumers who obtain their healthcare from 
these preferred providers. The main reason for choosing a PPO in preference to an HMO 
is the fact that it enables consumers to retain an element of choice in respect to their 
healthcare provider. This is an important factor for many Americans who have become 
used to complete freedom with respect to choosing their physician.
Like HMOs, PPOs achieve cost savings through use of formularies and encouragement of 
cost-effective prescribing practices. However, They do not have the benefit of a high 
degree of conti'ol over the physicians working under their plan which increases the 
difficulty in enforcing such measures. A significant number of PPOs have recently 
applied to obtain a licence to allow them to assume some of the financial risk involved in 
healthcare provision. This would take the form of capitated aiTangements with a number 
of physicians, though they would remain differentiated from HMOs since they would not 
have any restrictive control over the prefeiTed providers listed by their plan and by virtue 
of offering consiuners a choice of physician (in returm for financial forfeit).
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L 2 3  Exclusive Provider Organisations (EPOs)
These managed care plans fall halfway between PPOs and HMOs since they offer the 
same terms to physicians as PPOs in return for the same service but, like HMOs, they 
require their members to obtain their healthcare from the physicians listed by the plan (i.e. 
from the ‘exclusive providers’).
Despite a rapid initial growth in this type of plan, the penetration of EPOs is unlikely to 
increase at the same rate as HMOs and PPOs since it reduces consumer choice without 
having the means to control costs very rigidly. EPOs do not, therefore, offer a significant 
improvement over services which are already available through other organisations.
1,2 A. Physician Hospital Organisations (PHOs)
This type of organisation has arisen recently as healthcare providers see the need to 
become involved healthcare on a business level as well in a medical context. Physicians 
have progressed from entering managed care as a means of minimising losses to taking a 
proactive approach to this sphere of activity; a consequence of this shift in attitude has 
been the emergence of Physician Hospital Organisations. Alliances between HMOs and 
PHOs are rapidly increasing and this type of organisation is quickly assuming an 
important role within the managed care sector (personal communication 1998).
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These organisations take the form of joint ventures created by physicians or hospital 
managers principally for the purpose of negotiating capitation agreements with HMOs, 
The agreements drawn up usually require a PHO to treat all (or a specified number of) an 
HMO’s patients in respect of a certain disease or group of diseases in return for a fixed 
fee. The physicians’ motive in setting up these organisations is that, once an agreement 
has been signed, the PHO concerned has effectively reduced competition for patients and 
has a guaranteed source of patients from each HMO with which it is contract. The benefit 
to patients is that, by virtue of the capitation agreement negotiated between their HMO 
and the healthcare providers, care can be provided more cheaply than it would normally 
be, thus helping to keep premiums down.
7.2.5 Point o f Service Plans (POS Plans)
This recent development represents a further fragmentation of the managed cai'e maiket 
since the aim of POS plans is also to provide a service which falls midway between 
HMOs and PPOs i.e. between rigorous cost-containment and complete freedom of choice. 
Point of service plans use a network of contracted providers from which enrolled 
members select a primary cai'e physician to meet their healthcai'e needs. This physician 
also acts as a gatekeeper to control specialist services and hospital referrals. Care from a 
network provider is free to the patient at the point of service. However, unlike most 
HMOs care is also available from other physicians; for care of this nature the enrollee 
must pay at the point of service and is partially reimbursed at a later date. Financial 
incentives exist for physicians to refer enrollees to network specialists and other
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providers, since use of network providers is the principal means of controlling costs 
through monitoring programmes and agreed discounts.
The benefits to consumers of these new point-of-service plans are:
- they offer consimiers the freedom to change providers without changing their healthcare 
plan
- plan managers are able to extend their provider networks without being forced to make 
expensive investments (which many HMOs are likely to incur since their networks are 
often expanded by increasing the number of physicians employed by the plan).
- they are in a strong position are in a strong position to draw in more enrollees since they 
combine familiar' indemnity services with many of the benefits of an HMO.
From the above examples it is clear that there is a strong correlation between the degree 
of control which is a managed care managed company has over healthcare providers and 
it’s ability to control healthcare costs.
In addition to the plan operators described above, there ar e other players within the 
managed care environment who offer additional services to employers and consumers to 
ease the burden of their healthcare expenses. One of these are Pharmacy Benefit 
Managers who play a crucial role in the source of data for this analysis.
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1.2.6Pharmacy Benefit Management Companies (PBMs)
PBMs have received significant attention following the acquisition of the three lar gest by 
Merck and Co., SmithKline Beecham and Eli Lilley. This type of company is often a 
subsidiary of broader managed care organisations and it’s role is to take the expertise 
gained from involvement with managed care plans and market that knowledge to HMOs, 
PPOs, third party administrators, self-insured employers etc., to advise them on how best 
to contain their prescription drug costs. PBMs in the US now cover approximately five 
times more patients than at the beginning of the decade.
In effect, PBMs act as consultants to healthcare providers and plan managers advising 
them on how to best reduce their pharmacy costs. As such, they add another layer of 
administration between drug manufacturers and plan managers/healthcare providers since 
their role includes purchasing pharmaceutical products from manufacturers on behalf of 
their own customers and their money is made by charging customers management fees in 
return for their services.
However, PBMs are in a strong position to oust traditional wholesalers and other 
distributors since their unique advantage is that they also encompass a wide range of cost- 
effectiveness techniques such as drug utilisation reviews and drug effectiveness 
comparisons, strict formulary management, outcomes analysis, generic substitution and 
emphasis on preventative medicine.
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1.2.7 United Health Care, SmithKline Beecham and DBS
In May 1994 SmithKline Beecham announced it’s $2,3 billion acquisition of DPS from 
United Healthcare, together with a minimum six year alliance with United, through which 
SB had exclusive rights to data on United’s 1.6 million members.
DPS directly manages pharmaceutical benefits for 11 million people, placing it in third 
position after it’s two main competitors, PCS (51 million) and Medco (33 million). SB 
intended to use the patient data to conduct outcome studies and develop disease 
management programmes. United was to continue to use the services of DPS for all it’s 
HMOs.
DPS was founded in 1976 and incoiporated In 1988, achieving sales of $142 million in 
1993 (up from $43 million in 1992) with operating income of $39.9 million. It has been 
one of the fastest growing PBMs and is one of the largest, being used by around 300,000 
physicians. It has a network of over 30,000 pharmacies, both chains and independents, 
representing over third of the US total. DPS claims to have been the first PBM to:
- develop formulaiies in open panel healthcare system HMOs.
- introduce mandatoiy generic drug programmes.
- install point-of-sale claims processing.
- create manufacturer volume purchase programmes for managed care.
- undertake drug outcome studies.
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- introduce a national drug formula for self funded employers.
The SB deal differed in that it also included the tie-up with an HMO, bringing additional 
benefits, most notably, the exclusive right to supply PBM services to United’s ciUTent 
and any of it’s future owned HMOs. United was negotiating to acquire two additional 
non-staff model HMOs and indicated that it would use the proceeds of the DPS sale to 
fund an expansion programme.
SB highlighted (Pharmabusiness Report 1994) two key factors in determining the choice 
of DPS as a partner:
- the high proportion of HMO enrollees within it’s foimulary lives - whereas Medco and 
PCS (rival PBMs) ar e more directed towaids employee health schemes, HMO lives 
represent 61% of DPS total coverage.
- it’s experience of full capitation. As a result of it’s United parentage, DPS has extensive 
experience of capitation.
1.3 Cost efficiency mechanisms and the emergence of health care data.
In order to control healthcare costs, managed care companies and Pharmacy Benefit 
Managers use a range of techniques centred around:
- the collection and interpretation of patient and product information to enable plan 
managers to implement more efficient health care polices
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- financial tools generally aimed at getting the maximum amount of healthcare for a 
predetermined price.
The first of these particularly focuses on the drug utilisation review and provides a hint to 
the potential use of routinely collected data in health economics. DUR is an essential tool 
for managed care companies. They are achieved through the maintenance of complex 
databases of patient and product information which is then used to analyse and compare 
the cost-effectiveness compared to hospital treatment and to encourage prescribers and 
other healthcare providers to use the therapy which represents the best overall value for 
money in the long term.
There are three time frames which govern DUR techniques each of which can be used in 
isolation, but which together give managed care operators a very detailed picture of the 
impact an outcomes of the seiwices they provide (Albem 1990).
Prospective DUR: occurs before the prescription is written and operates by profiling 
physicians who do not adhere to formularies and informing them of how to change their 
prescribing habits.
Concurrent DUR: occurs after the prescription is written but before it is dispensed by 
picking out ‘outlying; drugs.
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Retrospective DUR: occurs over a period of time after the prescription has been 
dispensed. This fits best with economic evaluation and involves a complex review of all 
aspects of the products usage including effectiveness in each patient, dosage required to 
produce results, min-max. dosage taken, degree of compliance etc. to be used for 
comparative studies and cost effectiveness.
DUR is carried out by a number of parties. In some instances HMOs collect their own 
data and have dedicated employees or even separate subsidiaries whose role is to cany 
out analyses, to telephone physicians where necessary and to draw up str ategies for the 
future with respect to the company’s approach to cost effective healthcare provision.
Some HMOs store their own data and carry out in-house analysis but then use their 
network pharmacists to interact with the physicians in their locality to increase 
compliance with the plan’s objectives.
The explosion in the computerisation of health care data therefore stems from the original 
concept of tracking charge data within the accounting systems of healthcare institutions 
and providers, predominantly in tlie US, through to complete reviews of the costs and 
effects of prescribing decisions. Where as once we would have had to sort through 
medical records manually, we can now routinely access the same data, through 
computerised records, at apparently low cost and inconvenience down to the patient level.
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The advantages for this type of data 
are clear and include:
- the size of the population contained in the databases relative to other forms of patient 
data e.g. clinical trials
- the ability to examine trends in resource use over time
- the ability to examine patterns of care and treatment pathways.
- assessments of the resource impact of new medicines
However, more importantly for health economics, the real life and population based 
nature of claims databases means it should be possible to generate information with a 
high degree of external validity.
Despite the dramatic growth in this type of data, and potential for increasing the external 
validity of health economic studies, the applicability of it to health economics (in the 
pharmaceutical industry) has yet to be explored.
lA  Hypotheses to be tested.
This analysis seeks to test the following hypotheses.
Claims databases can provide accurate information on:
- prevalence and incidence of a disease.
- the type and level of services used in the management of a disease.
- what complications are caused by the disease
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- detemiine how much a specific disease costs in a managed caie setting.
- compare these findings with the available literature
To date, most work has only discussed the value of databases using qualitative 
assessments. This work aims to examine the type, and value, of data that can be extracted 
following an attempt at a quantitative evaluation. We will then explore the issues 
highlighted by this study on the use of databases in HE and suggest how/when this 
information could be used in developing an economic assessment of a medicine.
We have chosen to start this assessment by examining the case of otitis media in children 
using an analysis perfonned with claims data from the United Healthcare Corporation 
HMO health care plans. Specifically, and in relation to the generic objectives outlined 
above, the purpose of the UHC analysis was to deteiinine:
1) the prevalence of otitis media in the study population for the period 07/01/92-06/30/94.
2) what health services and therapy options are employed in the diagnosis and treatment 
of otitis media.
3) what serious complications are present in this population as a result of chronic otitis 
media.
4) what are the costs associated with the diagnosis and treatment otitis media in a 
managed care setting.
5) what are.the comparative costs of treatment of acute and chronic otitis media in a 
managed care setting.
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6) what are the comparative costs of treatment of acute and chronic otitis media when the 
initial antibiotic used in amoxycillin vs. amoxycillin/clavulanate vs. cefaclor.
1.5 Acute otitis media
Otitis media is a common infection of infancy and early childhood, with a peak age- 
specific incidence between the ages of 6 and 18 months. By 3 years of age, approximately 
three quaiters of children will have had at least one episode of acute otitis media, more 
than one third will have had recunent infections defined as three or more episodes, with 
incidence decreasing significantly after 6 years of age (Klein 1994).
In accordance with it’s high prevalence, otitis media accounts for a considerable 
proportion of health care costs. It is estimated that 25% of all prescriptions in the US are 
fort treatment with oral antibiotics for acute otitis media. The cost of managing the 
disease in the US has been estimated to exceed $3.5 billion (Graham 1994).
Otitis media may be cause of fever significant pain and hearing loss in children. There is 
also concern that associated hearing loss may adversely affect speech and language 
learning and also the development of cognitive abilities. Although tliere is little consensus 
regarding these issues, it can be argued that aggressive treatment can be justified because 
of the risk of long term impairment of communication skills.
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The condition can be divided into four clinical classifications; without effusion, acute, 
with effusion, and chronic (Thoene 1991). Otitis media without effusion can occur in the 
early stages or during resolution of the acute disease and, depending on duration, can be 
acute, sub-acute or chronic. Acute otitis media applies specifically to the rapid onset of 
the signs and symptoms of inflammation of the middle ear. Otitis media with effusion 
refers to the presence of fluid in the middle eai' and is differentiated from the acute form 
by the absence of the signs and symptoms of acute middle ear inflammation. The 
condition can be further classified according to the type of effusion (serous, mucoid or 
purulent) and it’s duration; acute (less than 3 months) and chronic (symptoms greater than 
3 months) (used for this analysis).
The middle ear consists of three principal structures; the tympanic membrane, auditory 
ossicles and eustachian tube. Acute otitis media in early childhood appears to be related 
in lai'ge part to eustachian tube dysfunction. The eustachian tube has at least three 
important physiological functions in preventing infection and accumulation of effusion in 
the middle ear; protection against nasophaiyngeal sound pressure and secretions; drainage 
and clearance of middle eai' secretions into the nasopharynx; and ventilation of the middle 
ear to equilibrate gas pressure and atmospheric pressure. Infants are predisposed to otitis 
media because their Eustachian tubes are shorter, wider and lie more horizontally than 
those of older children and because development of the muscles governing opening and 
closing of the tube is incomplete.
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An acute episode of otitis media usually results from the following sequence of events 
(Thoene 1991); the patient has an antecedent condition (viral infection or allergic 
reaction) that results in congestion of the respiratory mucosa of the upper respiratory 
tract; congestion of the mucosa in the eustachian tube results in obstruction of the tube at 
its narrowest segment; the secretions of the middle ear* mucosa have no egress and thus 
accumulate; and if pathogenic bacteria that colonise the nasopharynx are present in the 
middle ear secretions prior to obstruction, they multiply, and an acute suppurative 
infection results.
The course of otitis media with effusion is less apparent. Fluid persists for weeks to 
months after every episode of acute otitis media, even though appropriate anti-microbial 
therapy has sterilised the middle ear.
1.5J Bacteriology
Although otitis media is defined as inflammation rather than infection, the majority of 
cases involve bacteria. Since isolation of the causative organisms is not generally 
attempted in an office setting, it is important that clinicians be familiar with the most 
common infecting organisms in order to choose the most appropriate tieatment regimen. 
Based on anatomy, it is not surprising that the most frequently isolated bacteria in middle 
eai* fluid are the same as those found in the nasopharynx. Streptococcus pneumoniae is 
consistently reported as the most common organism in otitis media causing 
approximately 30-40% of all cases (Edelstein 1988, Bluestone 1988).Heamophilus
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influenzae is the second most common bacterial pathogen and is isolated in 20% of cases. 
The percentage of H. influenzae strains that aie resistant to ampicillin and amoxycillin is 
increasing and accounted for 30% of isolates in several clinical studies of children with 
otitis media (Michaels 1981, Wald 1984, Lim et al 1980). Another common organism 
that appeal's to be increasing in frequency as a cause of otitis media is Branhamella 
catarrhalis, which has been reported in 7-20% of isolates cultured from middle eai* 
effusions (Van Hare 1987, Shurin 1987). Streptococcus pyogenes and Staphylococcus 
aureus are also isolated from middle ear effusions in otitis media, but with a frequency of 
less than 10% (Witt 1988).
1.5.2 Management o f otitis media
Complications resulting from acute otitis media such as menigititis and mastoiditis 
currently occur in less than 1% of cases (Marchant 1983). Other possible complications 
include perforation of the tympanic membrane, tympanic membrane scarring, ossicular 
discontinuity, facial paralysis and hearing loss (Roberts 1989, Tos 1988). In addition, 
recurrent episodes may lead to speech impaimient and leai*ning difficulties in small 
children (Brooks 1980, Menyuk 1980). Therefore, the primai'y role of antibiotic therapy 
in the management of otitis media is to prevent possible complications and provide 
symptomatic relief. The four key antibacterial agents used in the management of otitis 
media are presented below.
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Ampicillin: this was at one time the most commonly prescribed antibiotic for otitis media 
and was considered the antibiotic of choice (Michaels 1981, Howie 1972, Jones 1974, 
Feder 1982), although this in longer the case due to it’s limited spectrum of activity for 
example, H. influenzae (Thoene 1991). As a consequence, this was not included in the 
analysis as a distinct antibacterial grouping.
Amoxycillin: has the same antibacterial spectrum as ampicillin but differs in that it is 
better absorbed from the gastrointestinal tract. Therefore, a major advantage of 
amoxycillin over ampicillin is that it causes fewer gastrointestinal adverse reactions 
(Marchant 1983, Feder 1982). IN areas where the emergence of H. influenzae and B. 
cataiThalis is limited, amoxycillin remains the drug of choice for empiric therapy.
Amoxycillin-clavulanate: is an oral antibacterial combination consisting of the antibiotic 
amoxycillin and the B lactamase inhibitor potassium clavulanate. This widens the 
spectrum of activity to include B lactamase producing organisms such as H. Influenzae 
and B catan'halis. Therefore, amoxycillin tends to be used for ‘amoxycillin failures’ or in 
areas where B-lactamase producing organisms are common (Klein 1994).
Cefaclor: a second generation cephalosporin effective against the common organisms 
implicated in acute otitis media (Eli Lilley 1988) although some strains of B lactamase 
producing B catarrhalis are resistant to cefaclor (Berman 1983). Frequently used in the 
same way as amoxycillin-clavulanate.
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One frequently used non-antimicrobial therapy, employed in the management of otitis 
media are tympanostomy tubes. When a child with chronic otitis media fails to respond to 
phaimacological therapy or has documented hearing loss, a surgical opening of the 
tympanic membrane for the insertion of a ventilating tube (tympanostomy tube) may be 
indicated to equilibrate pressure and allow drainage of fluid from the middle ear*. 
(Edelstein, 1988). Almost all chronic effusions are at least temporarily eliminated after 
this procedure (Bluestone, 1988). In 1994, this was the most common surgical procedure 
perfonned on children in the United States (Vogelgesang, 1984) with an estimated one 
million children having tympanostomy tubes inserted each year, at an annual cost of 
about $1 billion (Mandel, 1984)
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2. Methods
The study was conducted using claims data for the period 07/01/92-06/30/94 from three 
UHC affiliated health plans. All three plans are independent practice association (IPA) 
plans providing coverage for physician, hospital and prescription drug services. The three 
plans were characterised as follows:
1) HMO 1 located in the Southeast with an approximate annual enrolment of 81,400.
2) HMO 2 located in the Northeast with an approximate annual enrolment of 175,700.
3) HMO 3 located in the midwest with an approximate annual enrolment of 99,000.
The combined approximate annual enrolment is 356,100.
2.1 Data sources
UHC’s database includes member and provider enrolment information, physician, health 
facility and pharmacy claims. All files are linked by a member identification number 
which is assigned to the member by the health plan at the time of enrolment. A claim 
form containing information needed for identification procedures, supplies and specific 
drugs must be submitted in order for a health care provider to receive payment for any 
services provided to an enrolled member. It is these claims that provide the data elements 
for UHC’s research database.
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2.2 Claims identification
To initiate the study, the research database was searched for all otitis media claims (using 
ICD-9-CM diagnostic codes found in the ranges of 381., 382., and 385.1 - 385.19) 
occurring during the study time period of 07/01/92 - 06/30/94. A total of 156,832 claims 
were identified. Table 1 summarises the claims by file origination ( either doctor or 
hospital) for four six month study periods by plan.
Eighty four percent of all claims for otitis media originated in doctor files. This is to be 
expected since otitis media is most often diagnosed and treated by physicians in an office 
based setting. The remaining sixteen percent of claims originated in hospital files either 
as a hospitalisation, an emergency room visit or an out patient clinic visit.
The claims were also examined by month of the yeai* in which the claim originated. 
Figure 1 visually portrays the information. The claims demonstrate a seasonal 
component; declining during the summer and autunm months and increasing during the 
winter and spring montlis. This trend is consistent with the medical literature ( Thoene 
and Johnson 1991) although possible reasons for this trend are not cited. Whether there 
aie environmental and social factors which conelate with this trend is not known. It 
should be noted that, regardless of time of year, there are always claims present in the 
data for otitis media.
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2.3 Case selection
A member was included in the study if he or she met the following criteria:
1. Age between 0 and 6 years as of June 30 1994 (high incidence period);
2. Continuous enrolment for the period of 07/01/91 - 06/30/94. For those members 
imder two years of age, continuous enrolment since birth was necessary.
These selection criteria were applied to the member list and resulted in a total of 7967 
members being eligible. Once identified all medical and pharmacy claims during the 
study period for each member were retrieved from the database and used for analysis and 
entered into a SAS database listings for each patient. The SAS system is a software 
system for data analysis and report writing and also enables you to store data values, 
retrieve them, modify data, compute simple statistics and create reports all in one SAS 
session. Further details on SAS and it’s related procedures can be found in the SAS User 
Guide, Version 6, SAS Institute Inc, Cary NC.
2.4 Assignment to acute or chronic media groupings
ICD-9 codes were utilised to develop algorithms for assignment of the 7,967 members 
identified by case selection into acute or chronic acute otitis. The definitions were as 
follows:
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1) assign a member to the acute group if at any time during the study period the following 
diagnosis codes were found in the claims history:
381-381.06... acute non-suppurative otitis media
381.4...non-suppurative otitis media not specified as acute or chronic (no previous 
evidence of OM therefore can’t be chronic)
382-382.02... acute suppurative otitis media 
382.04 unspecified suppurative otitis media 
382.9 unspecified otitis media
2) assign a member to the chronic group if at an time during the study period or in the 
year prior to the study the following diagnosis codes or events were found in claims 
history:
381.1-381.19...chronic serious otitis media
381.2-381.29...chronic muted otitis media
381.3...0ther and unspecified chronic non-suppurative otitis media
382.1-382.3... chronic suppurative otitis media
385.1-385.19... adhesive middle ear disease
The acute group was further examined to determine which members within that group 
had evidence of acute otitis media that, because of continuing occurrences or length of 
time a single occurrence or prior history of chronic otitis media would more appropriately 
be classified as a member with chronic otitis media. The definitions were developed after 
a review of the literature (Jung and Rhee, 1991, in particular) and were as follows :
3 or more acute episodes within a running six month period, 
or
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CPT codes 69433-69437...tympanostomy requiring insertion of ventilating tube 
or
CPT code 69424... ventilating tube removal when originally inserted by another 
physician, if the removal only occurred during the study period or in the year prior 
and there is no evidence of the insertion 
or
any acute episode occurs for which drug therapy continues at least 30 days after 
the acute diagnosis
The ability to invoke this assignment protocol is dependant on identifying episodes of 
otitis media. Algorithms were developed to group the otitis media claims for individual 
members into episodes of caie. The rules established to determine episodes of care are as 
follows:
1) Consider a drug claim for an oral antibiotic to be associated with otitis media if 
the gap between an office visit and the dmg claim is not greater than 3 days.
2) Consider any subsequent drug claim to be associated with the otitis media 
episode if the gap between the first drug claim and any subsequent drug claim is not 
greater than seven days.
3) Consider any subsequent office visit to be associated with the otitis media 
episode if the gap between the first office visit or the gap between the drug claim and a 
subsequent office visit is not greater than 30 days.
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4) In those cases where a drag claim precedes an office visit, consider the office 
visit to be associated with the drug claim if the gap between the drag claim and the office 
visit is not greater than 3 days.
Although completely arbitrary, these algorithms were based on UHC study 
protocols, expert opinion from physicians/UHC data managers and are consistent with 
similar studies in the area (White et al 1996).
2.5 Statistical methods
2,5.1 Explanation o f the statistical tests used.
Statistical tests can be divided into two major classes: parametric and non-parametric. 
Paiametric techniques make certain assumptions about the distribution of values in the 
population form from which samples are taken. Non-parametric methods do not involve 
assimiptions about the population. All the parametric tests used in this analysis contain 
the assumption that sample values have a normal distribution. Whether a non-paiametric 
or a parametric test is used it is assumed the sample data comes from random samples. 
Both groups of tests are also dependant upon the technique known as hypothesis testing.
Hypothesis testing is a method of choosing between a null hypothesis (normally stating 
there is no difference between the items under test) and an alternative hypothesis (a 
difference does exist between the items under test). Given a study with a single outcome 
measure and a statistical test, hypothesis testing can be summarised in three steps:
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1) choose the significance level of the test i.e. with what level of certainty do we want to 
accept/reject the null hypothesis, (traditionally at the 5% level i.e. a 5% chance the 
event is due purely to chance, and hence a reasonably robust level of assurance).
2) Conduct the study, obseiwe an outcome and compute the p-value (calculated 
significance level)
3) If the p value is smaller than the chosen significant level then reject the null 
hypothesis in favour of the alternative hypothesis; if not do not reject the null 
hypothesis.
2.5.2 Chi-square test
When dealing with categories rather than quantity variables and asking whether there is a 
significant difference between samples in proportions we have used a technique called the 
Chi-squaie test. This compares the frequency with which we'd expect certain 
observations to occur, if chance only were operating, with the frequency that actually 
occuiTed (Rowntree, 1983)
In this analysis, for the relationships of interest, tables of proportions were calculated 
from the SAS dataset (for an example see Appendix H, Table H-1). A null hypothesis was 
then set up for each relationship to be investigated; in all cases this stated that where 
differences were seen in the tabulated proportions, no significant difference actually 
existed. In order to reject the null hypothesis the calculated chi-squaie value had to be 
greater than that predicted at the 0.05 level of significance. Where this did occur, the null
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hypothesis was rejected and the alternative hypothesis, a significant difference does exist, 
was accepted.
The SAS PROC FREQ procedure was used to perform Chi-square tests on the items of 
interest. This is a procedure that is descriptive in the sense that it produces frequency 
counts and cross-tabulation tables, allowing the investigator to describe data in a concise 
way. It is also a statistical procedure allowing you to analyse the relationships among 
variables. Frequency tables show the distribution of variable values. Cross-tabulation 
tables show combined frequency distributions for two or more variables.
The relationships tested using the chi-square analysis were:
- did any of the HMOs have a true greater proportion of otitis media claims than the 
other two HMOs.
- did either gender have a true greater proportion of claims than the other.
- did either gender have a higher proportion of claims for chronic or acute otitis media, 
did any of the HMOs have a true higher proportion of inserting tympanostomy tubes
- did either gender have a true higher proportion of insertion of tympanostomy tubes.
- was there an association between use of tympanostomy tubes and antibiotic therapy.
Problems do exist with using the Chi-square analysis (Bland 1992). Firstly, the data must 
be in frequencies i.e. the number of discrete objects occurring in different categories. The 
Chi-square will normally give false results if applied to data concerning the proportion or 
percentages of occunences in the categories. Also, the categories must be mutually 
exclusive, so that one individual cannot be counted in more than one category.
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A further important restriction on this form of test is that there should not be many 
categories for which the expected frequency is small. Quite what is meant by small is a 
matter of dispute amongst statisticians but two rules of thumb have been suggested 
(Rowntree 1983):
- if the number of categories is greater than 2, no more than 1/5 of the expected 
frequencies should be less than 5, and certainly none should be less than 1.
- if the number of categories is 2, both the expected frequencies should be 5 or larger.
If it is found when applying the test that the first rule has been broken it may be possible 
to combine categories until the offending expected frequencies have been suitably 
increased.
2.5.3 T-Test
For testing between means of item relationships in the data set, we chose the t-test as our 
method of testing for significant differences in the mean. Hie t-test is a par ametric test of 
the difference between two samples. It is applicable only to data measured on an interval 
type scale (Bland 1992).
The null hypothesis of the t-test is that two sets of data are random samples from a 
common, normally distributed population, or from two identical normally distributed 
populations. Before applying this test we should have good reason not to suspect the 
variables measured don’t have a normal distr ibution, hi our analysis of items of interest, 
we have no reason to suspect then means do not come from a normal distribution.
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The null hypothesis adopted is that there is no difference between the means of the 
populations from which the two samples were taken. The null hypothesis assumes that the 
observed difference between the sample means is due to the sampling process. The 
alternative hypothesis is that there is a difference between the means of the two 
populations, a difference which is being accurately reflected in the samples. A 
significance level of 0.05 is generally accepted as the appropriate level of significance 
required.
In this analysis the mean was calculated for each item of interest and t-testing performed, 
using the PROC TTEST SAS command. This computes sample means for each of the 
two groups of observations and tests the hypothesis that tire population means are the 
same. Once performed (see Appendix II, Table II-7) a p-value of less than 0.05 was 
required to reject the null hypothesis i.e. there is a less than 5% chance that the means 
observed are not true differences. This is sufficient to reject the null hypothesis and to 
allow us to accept the alternative hypothesis that there is a difference between the means 
of the two samples.
The differences in means, for acute and chronic otitis media groups, tested in this analysis 
were:
- the number of acute and chronic otitis media episodes during the study
- the number of antibiotic claims
- the number of amoxycillin claims
- the number of amoxycillin/potassium clavulanate claims
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- the number of antibiotic claims per episode
- the total dmg cost per episode day
- the total cost per episode day
- amoxycillin used or not
- amoxycillin used first
- amoxycillin/potassium clavulanate not used 
amoxycillin/potassium clavulanate used first
- cefaclor used
- cefaclor used first
Also, a multiple t-test was performed for the total cost during an episode between each
initial antibiotic group. This test (performed by the PROC MULTTEST SAS procedure)
tests between means for a number of groups and replaces the need for performing 
individual t-tests. The hypotheses adopted still follow the same flow as for a ‘traditional’ 
t-test (i.e. null hypothesis assumes no difference) and the interpretation of the results also 
remains the same,
2.5A  Logistic regression
In a situation where we want to investigate the relationship between the variation in a 
number of variables we turn to techniques called multivariate analysis. Multi-variate 
problems are common in research and in recent years there has been a substantial
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development in statistical techniques and applications of multi-variate analysis. The 
multi-variate technique used in this analysis was logistic regression.
Multiple regression is a form of multi-variate statistics. Similar* to simple regression 
where we fist a best straight line through the points on. a scattergram and investigate the 
numerical relationship between variables, multiple regression works with one dependant 
variable (the outcome we are investigating) and many independent variables (the variable 
that predicts the association).
In fitting a statistical model to a set of data, sometimes the dependent variable is 
dichotomous, where as the independent variables are continuous, discrete or both. The 
form of regression used in this case is known as logistic regression (Johnston 1994). This 
applies maximum likelihood estimation after transforming the dependent variable into a 
logit variable (the natural log of the odds of the dependent occurring or not), hi this way, 
logistic regression estimates the probability of a certain event occurr ing. Thus, logistic 
regression calculates changes in the log odds of the dependent variable, not changes in the 
dependent itself as with linear regression.
For this analysis, we elected to use logistic regression as we wanted to investigate the 
relationship between the dichotomous variables of being prescribed certain dr*ugs as first 
line treatment, or not, and independent variables such as, for example, having chronic 
otitis media, or not, (i.e. discrete categories), and the patient’s age at the start of an 
episode (i.e. continuous in nature).
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Logistic regression also allows one to calculate odds ratios for individual risk factors 
where you believe a variety of factors may be contributing to the occurrence of certain 
events. Odds ratios are related to probability but the odds are defined as the number of 
persons who experience the event divided by the number of people not experiencing the 
event. An odds ratio of one implies the similar likelihood of an event occurring; the 
higher the ratio away from one the greater the odds of an event happening.
We chose a stepwise form of logistic regression due to the large number of independent 
variables that were included in a database of this size. A stepwise regression is performed 
by adding one independent variable at each step of the analysis until associations have 
been explored. The var iables that show the best predictive ability are then listed. This 
analysis was performed using the PROC LOGISTIC command of SAS on the database. 
The dependant variable (tire outcome of interest) needs to also be entered into the SAS 
command chain.
For example (see Appendix HI, Table III-15), if we wish to determine which variables 
best predict whether a person receives amoxycillin as the first drug in an episode to otitis 
media we took the following steps:
- set up the appropriate SAS commands with receipt of amoxycillin as first drug in an 
episode as the dependant variable.
- run the SAS programme in order to perform the regression calculations.
- the SAS outputs will list the variables which best predict whether a person received 
amoxycillin as first drug in an episode. An odds ratio less than one means the variable
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is NOT associated with receiving that drug and in some cases infers the other category 
is associated: an odds ratio greater than one implies it has a greater probability of 
influencing the outcome (dependant variable).
- from the odds ratios in Table HI-15 we can see the following have a greater 
probability of receiving amoxycillin as the initial antibiotic:
- episodes among members in the acute otitis media group
- episodes among members not enrolled in HMOl and HM03
- episodes among members with shorter length of episode
- episodes among members who do not have otitis media episodes in the previous
year; and
- episodes among members who ar e female
This procedure was performed to investigate predictors for the following groups:
- amoxycillin as the initial dmg
- amoxycillin/potassium clavulanate as the initial dmg
- cefaclor as the initial drug
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3. Data results
In the study population as a whole, for all otitis media codes combined, the prevalence 
rate for otitis media is 538 per 1000 members. Over 50% of all children between the ages 
of 0 and 6 years have had at least one claim for otitis media. Table 2 summarises this 
information.
It should be noted that the rates reported in this table are prevalence rates in the 
epidemiological sense, i.e. that fraction of members who have had otitis media (as 
evidenced by the presence of claims) during the study period. Incidence rates, the fraction 
of members who had the first occunence of otitis media during the study period, were not 
determined for this study.
As table 2 shows, the prevalence of otitis media differs by age group and plan. The 
highest prevalence are found among children between the ages of one and two years. 
Among one year old children, 74% (739 per 1000) of continuously enrolled members 
have had an otitis media claim. For children under 2 years of age, the prevalence 
increases to 79% (790 per 1000) of continuously enrolled members. These rates are 
similai* to those reported in clinical literature (Teele, 1989; Thoene and Johnson, 1991).
Among the individual plans the highest overall prevalence rate, 55% of continuously 
enrolled members (553 per 1000) was found in HM02. The lowest rate, 51% (507 per 
1000) was found in HMOl. Chi-square analysis of the association between plan and otitis
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media shows a significant relationship (appendix II-I). A greater proportion of members 
in HM02 have had claims for otitis media when compared to the other two plans.
Prevalence also differs by gender. Tables 3 and 4 summarise the information. In the study 
population as a whole, for all otitis media codes combined, the prevalence for all males 
(552 per 1000) is higher than for females (524 per 1000). Examination of the overall 
population by age group indicates that only in the 6 year* old do females have a higher 
prevalence than males (477 per 1000 females compared to 454 per 1000 males).
The chi-square analysis of the association between gender and otitis media shows a 
significant relationship (appendix II, Table II-2). A greater proportion of males have otitis 
media claims when compared to females. These results are similar* to other- 
epidemiological studies reported in the literature (Teele 1989, Thoene and Johnson,
1991).
3.1 Assignment to acute or chronic otitis media
Classification of members into acute or chronic otitis media groups suggests that in any 
plan between 49% and 53% of members with otitis media between the ages of 0 and 6 
would be considered chronic cases. For the overall study population 50% of all cases are 
classified as chronic. This result supports literature which identifies otitis media as a 
recurring disease in this population. Table 5 simimarises the results of this study group
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assignment for those members who met the inclusion criteria for selection into the study 
by gender and by plan.
Table 5 also provides the infoimation concerning gender and assignment to acute or 
chronic otitis media groups. For all HMOs combined 48% of males and 52% of females 
aie classified into the acute otitis media group. The opposite is true for the chronic otitis 
media group 52% of males and 48% of females aie classified into the acute otitis media 
group.
Among individual plans there was some variation to this general rule. In HMOs 1 and 3, 
greater than 50% of males assigned to the chronic otitis media group; in HM02, 50% of 
males are assigned to each group. For females, in HMOs 2 and 3 greater than 50% of 
females ai*e assigned to the acute otitis media group; in HMOl 49% of females are 
assigned to that group.
Chi-square analysis of the association between gender and assignment to acute or chronic 
otitis media group shows a significant association, (appendix II, Table II-3). A greater 
proportion of males are assigned to the chronic group when compar ed to females. The 
opposite is tr ue for assignment tot he acute group where a greater proportion of females 
are assigned. The gender differences found in this study are supported by the literature. 
(Teele, 1989).
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Assignment to the chronic otitis media group was determined using several definitions 
described previously. Table 6 provides this information concerning number of members 
assigned to the chronic group based on the various definitions. Although a member could 
be considered as having chronic otitis media for multiple reasons, the definition category 
for this table was determined based on the first indication of chronic otitis media found 
within the claims history. For this reason, the number of members who were assigned to 
the chronic otitis media group because of tympanostomy tubes is minimal in comparison 
to the number of members who have had tympanostomy tubes inserted; a chronic otitis 
media diagnosis should precede the insertion of tympanostomy tubes appear s to be the 
case in the study.
For all HMOs combined, the largest number of members (48%) were assigned to the 
chronic otitis media group due to antibiotic therapy lasting longer than 30 days. As noted 
previously, however, the association of antibiotic claims to a specific disease based on 
claims data has the potential for error and, therefore, may over report classification into 
the chronic otitis media group for this reason.
Another 21% of members were assigned because they had 3 or more acute episodes in a 6 
month period of time. Slightly less than one fifth (19%) were assigned because of specific 
ICD 9 codes for chronic otitis media,.
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3.2 Complications with otitis media
In a review of treatment options, Jung and Rhee (1991) suggested that complications 
from otitis media have significant morbidity. The complications identified are of two 
types - those occurring inside the confines of the temporal bone (including facial 
paralysis, perforation of the tympanic membrane, mastoiditis or hearing loss) and those 
occurring outside the confines of the temporal bone (including meningitis and abscesses). 
Jung and Rhee did not report prevalence rates for the complications identified, however, 
but did not suggest that these complications occur despite the use of antibiotics.
3.3 Prevalence o f complications associated with otitis media
The claims history for each member was searched for evidence of the presence of 
complications which may be related to otitis media. Specific ICD 9 diagnostic codes were 
selected based on the literature review (Meyerhoff, 1984; Jung and Rhee, 1991; Isaacson 
and Rosenfield, 1994):
315.3-315.39...development speech or language disorder 
320-320.9 ...meningitis 
322-322.9...meningitis of unspecified causes 
383-383.9...mastoiditis
384.2-384.25...perforation of tympanic membrane
385.0-385.09...tympanic scarring
385.2...acquired abnormality of ear ossicles
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385.23...0.sicular discontinuity
385.3-385.35...destructive cholesteatoma 
350-351.0...facial paialysis
386.3-386.35...labrynthitis
389.0-389.08...conductive hearing loss
389.2...mixed conductive and sensoineural hearing loss
389.8...0.her specified forms of hearing loss
389.9...unspecified heaiing loss
784.5...speech disturbances V41.2...problems with heaiing 
These codes were grouped into 11 complications as follows:
Meningitis (320-322.9)
Mastoiditis
Perforation of tympanic membrane
Tympanic scaning
Acquired abnormality of ear ossicles
Ossicular* discontinuity
Destructive cholsteatoma
Facial paralysis
Labrynthitis
Hearing loss (389.0-389.9, v41.2)
Speech and language disorders (315.3-315.39,784.5)
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Table 7 summarises the infomiation concerning the prevalence for the 11 complications 
for any otitis media diagnosis, for each plan separately and all HMOs combined. The 11 
complications were also examined based on the grouping of otitis media into acute or 
chronic cases. Tables 8 and 9 summarise this information while Tables 10 and 11 present 
the same information concerning complications for those members with and without 
antibiotic therapy for otitis media.
Hearing loss and it’s potential developmental sequelae, speech and language disorders 
were the two most commonly occurring complications. The prevalence rates are 33 per 
1000 otitis media members and 11 per 1000 otitis media members respectively.
The prevalence rates for these complications ar e higher among those members classified 
into the chronic otitis media group. For hearing loss the overall prevalence rate was found 
to be 49 per 1000 chronic otitis media members. Evidence of speech and language 
disorders were found among 15 of every 1000 chronic otitis media members.
Finally, a comparison of the prevalence of these complications between those members 
with otitis media who have not received antibiotic therapy for the condition and those that 
have received antibiotic therapy shows higher prevalence for treated members. This 
should not be interpreted, however, as indicating any association of complications with 
the use of antibiotics. It may suggest that, at least for this study period of 2 years, not 
treating otitis media episodes with antibiotics does not show evidence of higher 
prevalence rates of complications.
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Additionally, the compaiison of prevalence between treated and untreated groups may 
reflect differences in severity of otitis media not discernible with claims data. 
Complications may be higher in the group with antibiotic treatment because that group 
has a more severe condition.
3 A  Use of tympanostomy tubes in chronic otitis media
Clinical literature identifies tympanostomy tubes as an acceptable treatment option for 
children with chronic otitis media either unresponsive to continued, non surgical therapy 
or having episodes recuiiing with increasing frequency (Meyerhoff, 1981; Gates et al, 
1985; Jung and Rhee, 1991; Isaacson and Rosenfeld, 1994).
To determine which members with otitis media also had evidence of tympanostomy 
tubes, the claims history was searched for either an insertion of ventilating tubes or the 
surgical removal of ventilating tubes in the absence of an identified insertion. For the 
purpose of this study, identification of members who have had tympanostomy tubes was 
made from the group identified as having chronic otitis media.
Table 12 summarises the information by plan and gender for 771 members identified with 
tympanostomy tubes.
Overall, approximately 11% of members identified with chronic otitis media also had an 
adenoidectomy procedure meeting the criteria established during the study period.
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Overall, 11% of males and 10% of females with chronic otitis media also had claims 
evidence of adenoidectomy. Differences can be noted by plan. HM03 has the largest 
percentage of members who have had evidence of adenoidectomy while HM02 has the 
lowest. The comparison of these results with other studies could not be made.
No claims evidence of adenoidectomy was found for any member in the acute otitis 
media group. This result was as expected given the clinical recommendations for 
adenoidectomy in the treatment of otitis media.
3.5 Episodes o f care for otitis media.
For this study, an ICD-9 diagnosis code for otitis media was identified and the associated 
claims related to the index event grouped into an episode of care. The definitions used to 
accomplish this were defined previously since an episode of care was an important 
component in the ability to classify members into acute or chronic groups.
Although there are several possible ways of categorising the episodes of care identified 
for this study, five basic types were defined. They were:
1) episodes which are a single diagnosis event only.
2) episodes which initiate and end with a diagnosis (most often associated with an office 
visit) of OM i.e. includes a follow-up visit.
3) episodes which initiate with a diagnosis and end up with drug therapy.
4) episodes which initiate with drug therapy and end with a diagnosis
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5) episodes which initiate and end with drug therapy.
Table 14 summarises the categorisation of 18,397 episodes into these 5 episode types.
For HMOs 1 and 2, the most common episode of care type, accoimting for greater than 
50% of all episodes, is that which initiates with an office visit and ends with an office 
visit. This suggests that practitioners in these plans rely heavily on a follow up office 
visit for resolution of the otitis media problem. IN HM03, however, the most common 
episode type, accounting for 52% of the episodes, is that which initiates with an office 
visit and ends with drug therapy. In this place, a course of antibiotics is considered to be 
the final encounter.
The average length of days for an episode has been determined for each episode type 
based on the claims associated with the episode. For single diagnosis events this could 
only be determined as 1 day. Claims evidence beyond a single data of service could not 
be definitionally associated. Clinical literature was not foimd that reported the average 
length of an untreated episode of otitis media and, therefore, could not be applied to this 
data.
For episodes beginning and ending with a diagnosis event, the average length of an 
episode was determined from the initial date of service for the first event through the final 
data of service for the last event, inclusive. For those episodes where the last diagnosis 
event was a hospitalisation, the dischaige date was considered the final date of service.
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For episodes ending with an antibiotic claim the days supply based on the quantity 
dispensed was calculated and the last date of drug therapy was defined. This was then 
used as the final date of service. Given the definitional limitations of length of episode 
based on claims evidence, an overall average length of episode would not be a 
supportable calculation. It approximates, however, 21 days when single event diagnosis 
are removed. When the classification into acute or chronic group is considered, the 
average length of an episode for members classified as acute is 13 days; for members 
classified as chronic the average length of an episode is 36 days.
The average number of episodes during the 24 month study period for a member 
classified into the chronic group the mean number of episodes during the 24 month study 
period was 3.1. A t-test of the difference between number of episodes during the study 
and classification into acute or chronic otitis media found a significant difference 
(Appendix II n-7).
Over 50% of the identified episodes had a single office event associated with them as 
Table 15 summarises. Only a small number of episodes (4%) did not have an office event. 
For these 741 episodes the indexing otitis media diagnosis code appeared in either an 
emergency room or urgent care centime. The number of episodes with 4 or more associated 
office visits is, likewise, small. In each place, however, a small number of episodes had 
10 or more office visits associated with them. One episode in HM02 had 29 office visits 
associated with an episode of care based on the definitions of time windows specified for 
this study.
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The episodes of care that were defined for this study were then categorised into two 
groups based on whether or not there was claims evidence that an antibiotic was used 
during the episode either as a prescription or administered during that course of an office 
visit. A total of 13137 episodes were categorised with antibiotic claims. For the 
remaining 5,260 episodes claims evidence of antibiotic use during the episode was not 
found. This does not mean that an antibiotic may not have been used as claims data does 
not allow for the ability to track physician sampling, or claims for antibiotics for which 
the total amount claimed in dollars was less than the members co-pay.
3.6 Episodes o f care with antibiotic claims
The initial antibiotic claim within an episode of caie was identified for 3 specific 
antibiotics (amoxycillin, amoxycillin/potassium clavulanate, and cefaclor), any other 
cephalosporin, any other antibiotic, and no antibiotic. Witliin the ‘other cephalosporin’ 
category there was claims evidence of 8 pharmaceutical agents: cefixime, cefadroxil, 
cefuroxime, ceftriaxone, cefprozil, cephradine, cefpodoxime proxetil and cephalexin. The 
‘other antibiotic’ category included penicillins, tetiacyclins, erythromycins, and their 
related compounds. Table 16 summarises this information for the antibiotic initiated 
within the episode.
For all antibiotics and HMOs, as expected, the number of claims is higher in the chronic 
otitis media group than acute (Appendix in. Table H 2).
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During the study period, the number of antibiotic claims, the number of amoxycillin 
claims, the number of amoxycillin/potassium clavulanate were all higher in the chronic 
otitis media group than acute. Statistical tests confirmed these differences to be 
significant (Appendix n. Tables 118-10).
For all HMOs combined, amoxycillin is the initial choice for the largest percent of either 
acute or chronic episodes. Other antibiotics (including other penicillin, erythromycins etc) 
were the next most often prescribed, followed by amoxycillin/potassium clavulante and 
cefaclor, both of which are the initial antibiotic choice in less than 10% of all episodes. 
Slight differences aie noted among plans. Other cephalosporins are prescribed least often. 
Figures 2-6 visually portray this information which could be considered a maiket share 
for the initiating prescribing decision for the antibiotics understudy.
Amoxycillin is the antibiotic used most frequently as the initiating antibiotic in the plans 
individually as well. This result is similar* to that obtained by White et al 1996. The use 
of Augmentin and cefaclor as the initiating antibiotic is reasonably consistent across plans 
at approximately 6-10% of the episodes. The plans ai*e noticeably different, however, in 
the number of episodes for which no antibiotic can be found in the acute OM group. 
HMOl had the highest percentage of untreated episodes (43%) for members in that 
group.
Differences can be noted between members classified into the acute and chronic otitis 
media groups. Although the initial choice for the largest percent of episodes in either
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group, amoxycillin was the initial antibiotic in 45% of the episodes identified among 
members classified into the acute group; 32% of the episodes identified among members 
classified into the chronic group had claims evidence of amoxycillin as the initial choice.
The use of both Augmentin and cefaclor (as measured by per cent of episodes with each 
drug as the initial antibiotic) increased in the group classified with chronic otitis media. 
Across the three plans, each drug is the initial antibiotic in approximately 10% of 
episodes found among members in the chronic group. There is some difference in the use 
of these two antibiotics by plan. When compared with cefaclor, Augmentin is the initial 
choice in a greater percent of episodes in HM02; in HM03 cefaclor is the initial choice 
in a greater per cent of the episodes.
The results of statistical analyses support these observations. Tests of the differences in 
means for the group assignment show that amoxycillin is used in a greater proportion of 
episodes for members classified into the acute OM group (Appendix III, Table III-5). 
Results also show amoxycillin is used first in a greater number of cases in the acute otitis 
media group than chronic, implying it’s predominant use as a first line agent. Statistical 
tests confirm this is a significant difference.
Logistic regression of those episodes where amoxycillin is the initiating antibiotic 
produce odds ratios which show that:
1) episodes among members in the acute otitis media group
2) episodes among members not enrolled in HMOl and HM03
69
3) episodes among members with shorter length of episode
4) episodes among members who do not have otitis media episodes in the previous year; 
and
5) episodes among members who are female;
have a greater probability of having claims evidence of amoxycillin as the initial 
antibiotic (Appendix d ,  Table 111-15).
Results show amoxycillin/potassium clavulanate, other cephalosporins and cefaclor are 
used more in chronic otitis media cases than acute. Statistical tests confirm these 
differences are statistically different (Appendix HI -  Tables 7- 12).
Logistic regression results (Appendix d-Table 16) found several significant variables 
associated with the use of amoxycillin/potassium clavulanate first in an episode of OM.
The odds ratios indicate that:
1) episodes among members in the chronic otitis media group
2) episodes among members not enrolled in HM03
3) episode with more than one office or outpatient visit during the episode
4) episodes among members who are older
5) episodes among members enrolled in HMOl;
have a greater probability of having claims evidence of Augmentin as the initial antibiotic 
during an otitis media episode.
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Similarly, cefaclor is used more often among members who have been classified with 
chronic OM (Appendix III, Tables IH-9 and ni-10). Logistic regression shows some 
differences between episodes where cefaclor is the initiating antibiotic when compared to 
amoxycillin/potassium clavulanate when other significant variables are considered. 
Logistic regression results show that:
1) episodes among members not enrolled in HM02
2) episodes among members who aie in the chronic otitis media group
3) episodes with emergency room visits
4) episodes among members who have had episodes in the year in the year prior to the 
study
5) episodes among members who aie female
have a greater probability of having claims evidence of cefaclor as the initiating antibiotic 
during an otitis media episode (Appendix m. Table HI-17).
Table 17 provides summary information concerning prescribing patterns for those 
episodes where claims for an initiating antibiotic can be identified. The majority of all 
episodes (63%) are resolved with a single course of therapy based on the evidence 
contained within claims data. For the specific antibiotic groups under study, 68% of 
episodes for which amoxycillin was the initiating antibiotic resolved with a single course 
of antibiotic therapy. Augmentin had 56% of episodes; cefaclor 59%; and other 
cephalosporins 58%. All other antibiotics as a group had 59% of episodes resolved with a 
single course of antibiotic therapy.
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When the number of episodes with 2 antibiotic claims are considered, approximately 82% 
of the 13,137 episodes identified with associated antibiotic claims are resolved with what 
may be considered judicious use of antibiotics. Nonetheless there aie present a number of 
episodes that show evidence of repeated use of antibiotics. Across the three plans, there 
was 165 episodes which had 10 or more associated antibiotic claims. HMOs and 2 both 
had where 20 or more antibiotic claims were associated with an episode.
For those episodes where more than one antibiotic claim was identified the second 
antibiotic claim was determined. The pattern that emerges is that whatever the initial 
choice, the secondary therapy will be the same drug for the largest percent of episodes. 
Thus, initial treatment with amoxycillin is followed by second therapy with amoxycillin. 
This is the case for both acute and chronic cases of otitis media (Appendix IV, Table IV - 
1).
When the second antibiotic claim has been issued by the same provider as the first, there 
is a greater percentage of episodes for the same antibiotic. When a different provider has 
issued the second prescription, the largest percent of episodes have secondary therapy the 
same but it is consistently less than that seen when the same provider has issued both 
therapies. Acute and chronic otitis media cases show the same pattern (Appendix V, 
Tables IV-2 andIV-3).
It should be noted that the reasons for re-prescribing cannot be deteiinined from claims 
data. Whedier re-prescribing may be the result of treatment failure, non compliance, 
patient dissatisfaction with the dosage form may not be ascertained within the boundaries 
of claims data.
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3.7 Episodes o f care with no initiating antibiotic therapy
Across all plans for approximately 28% of the otitis media episodes summaiised in Table 
16 claims for antibiotic therapy were not identified. When acute or chronic otitis media 
group is considered, 31% of the episodes in the acute otitis media group did not have 
claims evidence of antibiotic use. HMOl had the highest percent of acute otitis media 
episodes with no antibiotic claims, followed by HM03. For chronic otitis media, HM02 
had the highest per cent of episodes with no antibiotic claims followed by HMOl. 
Comparison of this result with other studies could not be made. Clinical opinion is such 
that the decision not to employ antibiotics in the treatment of otitis media is a valid 
option. Not all factors which may contribute to this decision can be assessed in claims 
data, however, two factors, a differential diagnosis of non suppurative vs suppurative 
otitis media and the presence of tympanostomy tubes during the identified episodes could 
be examined.
The episodes were examined to determine if a differential diagnosis may have contributed 
to the decision concerning use of an antibiotic therapy at the start of an episode. The 
classification of non-suppurative vs suppurative otitis media was made using the ICD-9 
groupings of otitis media and are as follows.
381-381.4.,.non suppurative otitis media
382-382.4...suppurative otitis media
382.9...otitis media, not otherwise specified 
Table 18 summarises this information.
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Chi-square analysis of the association between differential diagnosis and use of an 
antibiotic found a significant association (Appendix El, Table EI-I). A smaller proportion 
of episodes with a non-suppurative diagnosis of otitis media during the episode had 
claims evidence of antibiotic therapy than would otherwise have been expected.
Antibiotic therapy is generally employed, for treating episodes of otitis media for which 
the differential diagnosis is suppurative otitis media or is not specified as to type. There 
are, however, a large number of episodes (1878) for which a differential diagnosis of non­
suppurative otitis media appeared in the claim.
The episodes were also examined to determine if the presence of tympanostomy tubes 
may be an explanatory factor between episodes with and without claims evidence of 
antibiotic use. Table 19 summarises this information
Chi-square analysis of the association between antibiotic therapy during an episode and 
the presence of tympanostomy tubes establishes a significant association (Appendix E, 
Table E-7). when tympanostomy tubes are present a smaller proportion of episodes have 
associated antibiotic therapy than would otherwise be expected. When tympanostomy 
tubes are not present a larger proportion of episodes have associated antibiotic therapy 
than would otheiivise be expected.
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3.8 Costs associated with the treatment o f otitis media
For the purposes of this study health services and associated costs were grouped into four 
categories. Standard and plan specific CPT-4 and ICD-9 procedure codes were 
incorporated into a computer algorithm for assignment into the categories which were 
defined as follows:
1) Group 1: Physician Office/Outpatient Services
Claims with an ICD-9 code indicating otitis media or related diagnoses which could be 
identified as originating in physician offices or other outpatient facilities such as 
independent laboratories, one day surgi-centies, hospitalisations of less than day, 
audiology services and speech pathology seiwices. The relevant ICD-9 codes aie:
381-381.4...non-suppurative otitis media and eustachian tube disorders 
381.5-381.9... Eustachian salpigitis and other non specified disorders of Eustachian tube
382-382.9.,.suppurative and unspecified otitis media
385.1-385.19...adhesive middle ear disease 
384.2x...perforation of tympanic membrane
384.9...unspecified disorder of tympanic membrane
388.6...0ttorhia
388.7...0talgia
388.8...0ther disorders of the ear
388.9...unspecified disorder of eai*
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Group 2: inpatient Hospitalisations
Claims identified as hospital admissions of minimally one night with an ICD -9 diagnosis 
code for otitis media or the other related conditions specified in the study protocol in the 
piimaiy or secondary position (hospitalisations for which the admission and discharge 
day were the same date of service were assigned to the outpatient services).
Group 3: Emergency services
Claims with an ICD-9 codes in the in the primary or secondary position which could be 
identified either by coding conventions or site codes as originating in an emergency room, 
emergency services or urgi-centre.
Group 4: Drugs
Claims for prescriptive services or drags administered in the physician’s office for the 
pharmaceutical agents utilised in the treatment of otitis media. These included any of the 
following therapeutic classes and generic codes of drugs from UHC formulary:
021100 cephalosporins 
021300 clindamycin 
021400 erythromycin 
021500 penicillins 
021600 sulfonamides 
021700 tetracyclines 
071000 drugs affecting the ear 
152200 decongestants
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152300 combination antihistamine/decongestants 
generic code 03643 
generic code 09248
Dollars expended on health sei*vices associated with the diagnosis and treatment of otitis 
media totalled $2,744,819 across all plans for the 24 month period. Although a 
substantial dollar amount, this represents only a 0.4% of the total dollars expended by the 
3 plans on behalf of all insured members for the same 24 months, an amount which 
equalled £616,509,537.
The cost centre accounting for the largest percent of otitis media dollars, 72% was 
physician and outpatient services. This was followed by drugs used in the treatment of 
otitis media which accounted for 15% of the otitis media expenditure. Table 20 provides 
this information for each of the plans included in the study for each 12 month period and 
the 24 month study period. Figure 7 visually portrays this information for the study period 
of 24 months.
Tables 21 and 22 provide the same infomiation for those members classified with acute 
and chronic otitis media separately. Of the £2,744,819 of this total ($2,301,155) is 
expended on otitis media episodes for members classified into the chronic otitis media 
group; 16% ($433,665) is expended on otitis rriedia episodes for members classified into 
the chronic otitis media group. Thus, 50% of the members with claims for otitis media
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during the study period account for 84% of the total dollars expended by the health plans 
for this condition.
Statistical tests show the drug cost and total cost per episode is significantly higher in the 
chronic otitis media (Appendix HI, Tables 3-4).
As expected, members with chronic otitis media have a lai'ger percent of dollars expended 
for physician and outpatient services when compared to the acute cases. Acute cases, 
however, have a larger percent of dollars expended on emergency services and in-patient 
hospitalisations. Figure 8 visually portrays information.
Associated costs for chronic otitis media were also determined by chronic categorisation. 
Appendix V provides this information for all HMOs combined for each of the five 
assignment definitions, namely:
1) presence of an ICD-9 code for chronic otitis media
2) length of a single episode greater than 30 days
3) antibiotic drug therapy greater than 30 days
4) presence of tympanostomy tubes
5) having 3 or more otitis media episodes in a 6 month period
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3.9 Costs associated with the treatment o f otitis media by initiating antibiotic
Table 23-25 provide information concerning the costs associated with the treatment of 
otitis media when the initiating antibiotic is considered. Table 23 provides the 
information for all HMOs combined for all otitis media episodes. Table 24 provides the 
same information for episodes which occurred among members classified into the acute 
otitis media group. Table 25 provides the information for episodes which occurred among 
members classified into the chronic otitis media group. Appendix 1 provides the cost 
information for each plan separately. The costs centres ai*e as previously reported, 
namely:
1) Group 1 : Physician Office/Outpatient services
Claim with an ICD 9 code indicating otitis media or related diagnoses which could be 
identified as originating in physician offices or other outpatient facilities such as 
independent laboratories, one-day surgi-centres, hospitalisations of less than 1 day, 
audiology seiwices and speech pathology services.
2)Group 2: Inpatient hospitalisations
Claims identified as hospital admissions of minimally one night with an ICD-9 diagnosis 
code for otitis media or the other related conditions specified in the study protocol in the 
primaiy or secondary position. Hospitalisations for which the admission and discharge 
date were the same were assigned to outpatient services.
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3) Group 3: Emergency services
Claims with an ICD 9 diagnosis code in the primaiy or secondary position which could be 
identified either by coding conventions or site code as originating in an emergency room, 
emergency service centre or urgi-centre.
4) Group 4 : drugs
Claims for prescriptive services or drugs administered in the physician’s office for the 
pharmaceutical agents utilised in the treatment of otitis media, therapeutic classes and 
generic codes of drugs from the DPS formulaiy specified previously have been used.
As Table 23 shows, regardless of grouping into acute or chronic otitis media, when an 
episode does not have claims evidence of antibiotic use, the average amount paid per 
episode is approximately $87. Physician and outpatient services account for 
approximately 82% of the total costs for those episodes, emergency services 
approximately 9% and inpatient hospitalisations approximately 10%. Drug costs aie 
minimal since there was no evidence of oral antibiotic use associated with the episode. 
The costs which appear in this category are for otic drops, primarily.
When evidence of oral antibiotic use during an episode can be found within the claims 
data the average amount paid per episode increases, ranging from $126 per episode for 
those episodes where amoxycillin is the initiating antibiotic to $255 per episode when 
cefaclor is the initiating antibiotic. When compared to episodes where there is no
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evidence of oral antibiotic therapy, the per cent of total costs expended in physician and 
outpatient services, emergency services and hospitalisation are less..
Table 23 shows there is $40 less in the average amount paid per episode for episodes 
where amoxycillin/potassium clavulanate is the initial antibiotic used during an episode 
compared to those episodes where cefaclor is the initial antibiotic used during an episode. 
This is a statistically significant amount. (Appendix IE, Table 18)
Cost per day of an episode was also determined and subjected to statistical analysis. 
These results show that there is a statistically significant difference between episodes 
where amoxycillin/potassium clavulanate is the initial antibiotic used during an episode 
and cefaclor is the initial antibiotic used. Cost per day is less for the 
amoxycillin/potassium clavulanate episodes.
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4. Discussion
This discussion has been broken down into 3 sections:
4.1 What answers were we able to derive on questions specifically relating to otitis 
media?
4.2 What methodological issues arose during the analysis?
4.3 How could this information be used in health economics reseaich in the 
pharmaceutical industry?
4.1 What answers were we able to derive on questions specifically relating to otitis 
media?
The discussion of results presented below proceeds in the order that research questions 
are outlined in the study proposal. Comments made are intended to act as a stimulus for 
broad discussion of the results among interested groups and identification of areas for 
further study.
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4.1.1 What is the prevalence o f otitis media in the study population for the period
The results of this study support the information which can be found in the clinical 
literature concerning the prevalence of otitis media in children. During the study period, 
across all ages, over 50% of children have had claims for otitis media. The highest 
prevalence was found in children less than 2 years of age. The data also indicated that the 
prevalence of otitis media differed by gender, being higher among members who are 
male. There were also differences in prevalence rate by plan suggesting that there may be 
a geographical component potentially related to location.
It is possible that otitis media prevalence rates may also differ due to socio-economic 
status. This has been noted with other diseases. The plans which were available at the 
time of this study did not allow for the examination of this question, however, the 
inclusion of different plans, some of which have Medicaid enrolment, may provide 
information related to such a relationship.
4.1.2 What health seiyices and therapy options are employed in the diagnosis and 
treatment o f otitis media?
For a large number of the episodes of otitis media (74%) a conservative approach to the 
treatment option (either no treatment with an antibiotic or single antibiotic therapy) is 
found. The majority of all episodes (63%) aie resolved with a single course of therapy
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based on the evidence contained within claims data. For the specific antibiotic groups 
under study, 68% of episodes for which amoxycillin was the initiating antibiotic resolved 
with a single course of antibiotic therapy. When the number of episodes with 2 antibiotic 
claims are considered, approximately 82% of the 13,137 episodes identified with 
associated antibiotic claims are resolved with what may be considered judicious use of 
antibiotics.
For those episodes where more than one antibiotic claim was identified the second 
antibiotic claim was deteimined. and the pattern which emerges is: whatever the initial 
choice, the secondary therapy will be the same drug for the largest percentage of episodes. 
Thus initial treatment with amoxycillin is followed a second course of therapy.
When the second antibiotic claim has been issued by the same provider as the first, there 
is a greater percentage of episodes for the same antibiotic. When a different provider has 
issued the second prescription, the laigest percent of episodes have secondary therapy the 
same, but it is consistently less that seen when the same provider has issued botli 
therapies. The results, in part, substantiate the claims that provider preferences and 
familiarity with pharmaceuticals play a role in prescribing and re-prescribing patterns.
It should be noted that the reasons for re-prescribing cannot be detennined from claims 
data. Whether re-prescribing may be the result of treatment failure, patient non- 
compliance, patient dissatisfaction with the dosage foim, or adverse events, may not be 
ascertained within the bounds of claims data. This would be important information to
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consider, particularly in those instances where re-prescribing is the result of treatment 
failure.
A total of 771 members (19% of the members with chronic otitis media) had claims 
evidence of tympanostomy tubes. Significant association was found by plan suggesting 
that there is some regional differences in the use of tympanostomy tubes. The nature of 
this difference may be of further interest but the ability to explore this difference may not 
be possible within the boundaries of claims data.
Chi-square analysis also found gender to have a significant association. A greater 
proportion of males had claims evidence of tympanostomy tubes. It was also found that 
tympanostomy tubes are a contributing factor in the decision not to use antibiotics during 
an otitis media episode, as one would expect. Nonetheless, a number of members (786) 
received an antibiotic while tympanostomy tubes were present. Whether this represents 
necessary duplicative therapy cannot be determine with claims data.
Claims evidence of adenoidectomy were found for 434 (11%) of members with chronic 
otitis media. There were no members classified in the acute otitis media group with 
claims evidence for this procedure.
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4.1.3 What serious complications are present in this population as a result o f chronic 
otitis media?
Of the 11 complications examined in this study, hearing loss and the related 
developmental sequelae of speech and language disorders were the two most common 
complications at prevalence of 33 per 1000 otitis media members and 11 per 1000 otitis 
media members respectively. Prevalence differences were found among members 
classified with acute or chronic otitis media. As expected, prevalence rates were higher in 
the chronic otitis media group.
The clinical literature cited for this study did not report results. Further, the prevalence 
rates for hearing loss and speech and language disorders among members who do not 
have otitis media is not known. Further study of complications should begin by 
examining these comparative differences.
4.1.4 What are the costs associated with the diagnosis and treatment o f otitis media in a 
managed care setting ?
A  total of $2,744,819 were expended across the three health plans for the 24 month study 
period. The largest cost centre was physician and outpatient services accounting for 72% 
of the dollars. This is as expected since otitis media is considered to be a condition treated 
in the outpatient setting. Nonetheless, overall 7% of the dollars expended in treating otitis 
media are for in-patient hospitalisations and 6% for emergency services..
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When no oral antibiotic treatment can be associated with otitis media episodes, a greater 
percentage of total costs are expended in these two costs categories. The increased costs 
of drugs when claims evidence of oral antibiotics are found may, therefore, be off-set by 
the decreased percentage of costs of emergency services and inpatient hospitalisations. 
Psychological advantages may also accrue if antibiotic use decreases emergency services 
and in patient hospitalisations, particularly given that the population under study is a 
paediatric one.
4.1.5 What are the comparative costs o f treatment o f acute and chronic otitis media in a 
managed care setting ?
Although members classified with chronic otitis media make up 50% of the population of 
members identified with otitis media, they account for the largest portion of total dollars 
expended for this condition. Of the $2,744,819, 84% of this total ($2,301,155) is 
expended on otitis media episodes for members classified into the chronic otitis media 
group.; 16% ($433,665) is expended on otitis media episodes for members classified into 
the acute otitis media group.
As expected members with chronic otitis media have a larger percentage of dollars 
expended for physician and outpatient services when compared to the acute cases. Acute 
cases have a larger percent of dollais expended on emergency services and in-patient 
hospitalisations.
87
4.1.6 What are the comparative costs of treatment of acute and chronic otitis media when 
the initial antibiotic used is amoxycillin vs amoxycillm/clavulanate v.y cefaclor?
Regardless of grouping into acute or chronic otitis media, when an episode does not have 
claims evidence of antibiotic use, the average amount paid per episode is approximately 
$87. Physician and outpatient services account for approximately 82% of the total costs 
for those episodes, emergency services approximately 9% and inpatient hospitalisations 
approximately 10%. Drug costs are minimal since there was no evidence of oral antibiotic 
use associated with the episode. What costs appear in this category am for otic drops 
primarily.
When evidence of oral antibiotic use during an episode can be found within the claims 
data, the average amount paid per episode increases, ranging from $126 per episode for 
those episodes when amoxycillin is the initiating antibiotic to $255 per episode when 
cefaclor is the initiating antibiotic. When compared to episodes where there is no 
evidence of oral antibiotic therapy, the per cent of total costs expended in physician and 
outpatient services, emergency services and inpatient hospitalisations aie less.
The use of oral antibiotics during an otitis media episode contributes to an increase in the 
total average amount paid per episode but given the evidence, may be off set by decreases 
in the relative amoimts expended in some high cost centres such as emergency rooms and 
inpatient hospitalisations. This should not be overlooked in the discussion of the relative 
advantages of oral antibiotic therapy.
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When comparing the costs of episodes where amoxycillin/clavulanate is the initiating 
antibiotic with those where cefaclor is the initiating antibiotic, the average amount paid 
per episode is less with amoxycillin/clavulanate.. The $40 difference is a significant one 
and is consistently the same when acute or chronic otitis media grouping is considered. 
Given the differences noted in the logistic regression and discriminant analysis results 
this difference may be partially explained by the emergency services found to be a 
significant explanatoiy variable for cefaclor use. It may be that hospital based physicians 
may have more familiarity with cephalosporin antibiotics generally, and therefore 
prescribe them as a class more frequently.
Cost per day of an episode was also determined and subjected to statistical analysis. 
These results show that there is a statistically significant difference between episodes 
where amoxycillin/potassium clavulanate is the initial antibiotic used during an episode 
and cefaclor is the initial antibiotic used. Cost per day is less for the 
amoxycillin/potassium clavulanate episodes ($1.40 per episode day).
The largest cost advantage, however, is with amoxycillin. The cost difference between 
amoxycillin and amoxycillin/potassium clavulanate as measured by average amount paid 
per episode is $89. The cost difference as measured by cost per episode is $2.40.
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4.2 What methodological issues arose during the analysis?
Generally, the areas of debate in using claims data relate to validity issues i.e.:
- coding errors
- diagnosis
- linkage between the dispensing of a drug and the patients compliance, actual dosing, 
appropriateness of use etc.
- confidentiality
- appropriateness of the population of the databases to other settings of caie.
- the continuity of the patient records e.g. drop outs etc.
In the case of this analysis, there are four distinct aieas of debate:
1) Case selection
2) Group assignment
3) Assessment of complications with otitis media
4) Cost assignment
4.2.1 Limitations of case selection
As highlighted earlier, and as with all research studies, limitations must be placed on the 
ability to generalise the results beyond the sample and setting employed. This study 
adopted a traditional approach of case selection followed by assignment to groupings
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relevant to the overall analysis. The limitations that exist because of the case selection 
process adopted in this study include:
1. Representativeness
The study population is limited to those people enrolled in the three UHC model health 
plans. Therefore demographic factors, including socio-economic status and employment 
status, aie likely to make this population unique. Generalisation of results is appropriate 
only to similar populations.
2. Random selection
Because the database contains historical information randomisation, as employed in a 
conventional clinical trial, was not employed in this study. Any member meeting the 
inclusion criteria were entered into the study.
3. Geographical representativeness
The three health plans included in the study are located in three states. Some patient, 
provider and practice differences could not be identified from the UHC database. 
Caution should be exercised in generalising to other regions.
4. Date source constraints
Although claims data present unique advantages when utilised as a research tool, there 
are also constraints introduced (Ray, 1989 and Weiner, 1990).
The key constraints aie:
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a. Dependency on coding which because of variations in coding, errors in 
coding, incompleteness of coding and the non specificity of some coding, may result in 
errors of classification. No methods have yet been published on how to assess the 
magnitude and effect of these eixors.
b. The underlying purpose of claims data may contribute to errors of 
classification. Providers may submit claims for the sake of expediency of payment with 
less regal'd for the accuracy of the claim. This may contribute to over or under 
identification of disease episodes.
4.2.2 Limitations o f group assignment
Likewise with group assignment, errors will exist largely due to:
1) dependency on coding
Variation in coding, errors in coding, incompleteness of coding and the non-specificity of 
some coding may result in errors of classification. This may result in over or under 
identification of acute or chronic otitis media cases.
2) subjectivity of the diagnostic process
Medical literature suggests that the medical diagnostic process is a combination of 
science and art-dependant in many cases on the experimental component of the clinicians 
training. The decision to diagnose a presenting condition as acute or chronic acute otitis 
media is made by individual clinicians with varying levels of experience. This cannot be 
controlled for within the bounds of claims data.
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3) Heterogeneity of groups
Clinical opinion was utilised to determine the definitions for assignment into groups. In 
the case of chronic otitis media assignment was based on 5 different possible definitions. 
This may result in a group with greater individual differences than is apparent.
4) Definition of groups
Age in yeai's was assigned based on age at the end of the study period. Even so, there will 
be members who because of age less than six months, cannot be classified with chronic 
otitis media due to a lack of medical history.
5) tympanostomy tube indicator
any member included in this study with claims for tympanostomy tubes was categorised 
as chronic even though the tympanostomy tube procedure may have had a non otitis 
media diagnosis code associated with it (i.e. chronic tonsillitis or chronic sinusitis). The 
use of tympanostomy tubes as a treatment modality for other conditions has not been 
established but if nevertheless may, if employed, over assign some members into the 
chronic group.
6) definition of an episode of otitis media
the research questions for this study concern the antibiotic therapy employed in treating 
otitis media. Oral antibiotic drug claims were therefore used to determine episodes of 
care. Other studies may employ different index events to determine otitis media episodes.
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Comparison of the results of this study must take definitional differences into 
consideration.
In addition the association of a drug claim with a diagnosis code has the potential for 
eiTor. Particularly when a drug may be prescribed for a number of different conditions (as 
is the case with antibiotics) and the disease in question may have a number of associated 
conditions (e.g. pharyngitis, tonsillitis etc.), the assignment of a drug claim to a diagnosis 
could result in the over identification of drag treatment with one specific disease. In this 
analysis, potential errors were minimised by utilising short time windows.
7) detennination of time windows for episodes of care
The time windows employed in this analysis are aititraiy, though based on clinical/expert 
opinion..
4.2.3 Limitations to the assessment o f complications associated with otitis media
Some limitations should be considered in inteipreting the results related to complications 
associated with otitis media. The limitations include but are not necessarily limited to:
1) Association of complications with otitis media.
Claims data were searched for any evidence of complications among those members 
identified for this study. Whether the conditions occurred because of otitis media cannot 
be stated with certainty. Studies of the prevalence rates of these 11 complications in a 
population of 0-6 year old members not having otitis media were not performed.
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2) Diagnostic codes for hearing loss.
Only the presence of an ICD-9 diagnosis code for heating loss was used. Because tests for 
conductive hearing loss may be used in the differential diagnosis of otitis media, claims 
with CPT-4 procedure indicating hearing tests only were not included. This may result in 
the underreporting of hearing loss as a complication, the extent is not known.
3) Definitions of acute and chronic otitis media.
The classification of members into acute or chronic otitis media has limitations 
previously described. Comparative differences in the prevalence rates for the 11 
complications identified should also refer to these limitations.
4) Association of drug therapy with otitis media.
The association of any drug therapy with a specific disease is subject to eiTors of 
assignment. Members with evidence of antibiotic therapy during an otitis media episode 
may have had another condition for which the antibiotic was prescribed. Over reporting 
would result, the extent of which is not known.
4.2.4 Limitations o f cost assignment
Several limitations concerning the costs reported in this study should be noted.
1) Specificity of costs incuiTed by specified plans only.
The costs associated with the identified claims and reported for this study are the costs 
incuixed directly by UHC plans and the costs incurred by the patient as co-pay only. The
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amount reported does not include any amounts specified as the responsibility of another 
insurance program through co-ordination of benefits.
2) Format of inpatient hospitalisation charges
The ability to decompose inpatient hospitalisation costs into component costs (facility 
charges, pharmacy costs, etc.) does not exist. Therefore, the inpatient hospital costs 
reported are total costs paid for each hospitalisation with a primaiy or secondaiy ICD-9 
code of interest and length of stay of at least overnight.
3) Definition of direct costs
Dollar amounts reported are an assessment of direct costs only. For this study, direct costs 
are defined as those costs for which a managed care plan incurs costs. Other costs which 
may be defined as direct by other reseai'chers are not included , nor aie any indirect costs. 
Although indirect costs (including lost time from work or school, etc.) may increase the 
overall costs of otitis media, claims data do not allow for assessment of such associated 
costs.
4) Member eligibility
Costs of services included in the claims data of UHC plans are those for which a member 
has eligibility. The extent and costs of certain treatments aie not included in a benefit 
structure cannot be ascertained from this data source. In the case of otitis media this 
includes the extent and costs of OTC medications whose use may or may not be initiated 
as the result of physician recommendation.
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5) Co-pay benefit structures
The unreported use of any treatment whose total cost does not equal the costs assessed to 
the member as co-pay. Any pharmaceutical agent ordered by the physician in a quantity 
which results in costs less than member co-pay will be undeneported.
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4,3 How could this information be used in health economics research in the 
pharmaceutical industry?
Lair (1996) ai'gues that retrospective data sources can assist economic study data needs in 
seven ways.
1) identifying appropriate economic endpoints.
2) defining the patterns of usual care and specti um of current therapy.
3) deteimining episode duration.
4) highlighting adverse events.
5) determining sample size for economic endpoints.
6) identifying important economic stratifying variables.
7) quantifying compliance expectations.
Linking these areas to the otitis media analysis shows information in these areas can 
readily be extracted.
1) identifying appropriate economic endpoints.
In economic components of clinical trials, it is important to determine the usual 
progression of utilisation events that most accurately represent the course of treatment. 
These events mesh with and aie often responsive to the clinical paiameters measured in 
the study but are fax* less known. In addition, the aiTay of secondary endpoints are not 
easily identified prior to some initial analysis of the events hlcely to occur.
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In this study, the key cost driver was physician and outpatient services (72% of total 
costs). This was followed by dmg therapy (15% of total costs). Chronic otitis media 
consumed 84% of total costs i.e. 50% of members account for 84% of total otitis media 
incuned costs.
Within severity groups, chronic cases have the laigest percent of costs expended for 
emergency physician and outpatient services. Acute cases have the largest per cent of 
dollars expended on emergency services and in-patient hospitalisations.
This indicates the areas we should focus our attention on when collecting resource use 
data as pait of an economic trial.
2) defining the patterns of usual care and spectrum of current therapy.
Patterns of health care can be reconstmcted from administrative databases. For a 
particulai* diagnosis, treatment options can be arrayed and alternative therapies described. 
For example, is drug therapy the only option or are other procedures used.
In our study, a conseivative approach to treatment (no treatment or single antibiotic 
therapy) is adopted in 74% of cases. The majority of episodes aie resolved with a single 
course of drug therapy. For HMOs combined amoxycillin is the antibiotic used most 
frequently as the initiating antibiotic and is used in a greater proportion of acute cases. 
Amoxycillin/clavulanate and cefaclor showed increased use in the chronic otitis media 
group.
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In the cases of re-prescribing, it would appear that whatever the initial choice, the 
secondary therapy will be the same in the majority of cases.
Tympanostomy tube insertion is reserved for those patients in the chronic group only, 
confirming it’s use in ‘treatment failures’.
From all this data it should be possible to constmct a flow of patient pathways, along with 
probabilities of going down those routes with associated costs, in order to construct an 
economic model of treatment. From this we could construct a model investigating the 
possible impact of a new therapy along with appropriate sensitivity analyses to investigate 
the impact of certain key variables. Using estimates of possible effectiveness of a new 
drug, it would then be possible to derive a cost break-even price for a new drug (at 
vaiious degrees of effectiveness) to inform commercial pricing decisions.
3) determining episode duration.
Secondary data can portray the appropriate episode window for clinical and economic 
studies. If the episode is defined based only on the expected duration necessary to 
demonstrate clinical efficacy, the economic effects may be missed if the cost of the 
therapy process does not mirror the clinical efficacy pattern.
In this study the average length of an episode is 13 days for members classified as acute 
and 36 days for those classified as chronic. This would suggest we would need to collect 
data on chronic patients for neaidy 3 times longer than for acute. As we don’t know if an
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episode is going to acute or chronic at the outset, this would set the data collection period 
for all patients involved in an economic trial.
4) highlighting adverse events.
It is likely that many of the diseases under consideration for clinical trials will be chronic. 
Historically, it has been difficult to either identify subjects for a clinical trial that are free 
from confounding co-morbidities that could complicate the identification of adverse 
events or distinguish between symptoms of a co-morbidity and a potential adverse event. 
Claims data can be useful to address this issue.
Claims databases can also be useful in calculating the treatment cost of adverse drug 
reactions. These data can subsequently be used in different types of pharmacoeconomic 
studies.
hi this study, adverse events relating to pharmaceutical therapy were not assessed as part 
of this study. Complications arising from otitis media were showed to be hearing loss and 
speech and language disorders to be most prevalent. For some diseases, 
theoretically, we could have provided data on the distribution of co-morbidities in the 
population and used that to infer differentiation of adverse events and symptoms 
associated with the co-morbidities most likely associated with the primary diagnosis.
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5) deteimining sample size for economic endpoints.
Again, this was not considered as part of the original reseaich proposal, however, 
theoretically, the robustness of sample size calculations should be improved by actual 
estimates of the probability of occurrence of key cost drivers.
Otitis media is not necessaiily the easiest of conditions to highlight this potential aid to 
outcomes research. Instead, think of a database that could provide estimates of admission 
to nursing home for a particular condition e.g. dementia. We could extract estimates for a 
control group from such a database and use that rate of admission to calculate the precise 
estimates of the sample size necessary to detect potential differences between a conti ol 
group and treatment group.
6) identifying important stratifying variables.
Important stratification variables and randomisation criteria may not always be obvious in 
studies of clinical or economic outcomes. Basic descriptive analyses can be conducted 
using claims databases to help identify within and between group differences in disease 
prevalence, utilisation patterns or other factors.
In this study factors highlighted as having an effect on resource utilisation would appear 
to be: gender
location of HMO 
age of patient
acute Vs chronic disease classification
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This should help those individuals designing outcomes research trials to ensure an 
appropriate balance is secured between a control and active group.
7) quantifying compliance expectations.
Often clinical and economic trials assume full compliance with the target agent -  an often 
inaccurate assumption that can have a critical impact on outcomes assessment. This might 
be a reduction in the theoretical effectiveness of a drug, prolongation from a lack of effect 
or even unnecessary prescriptions.
Claims databases can be used to estimate baseline expectations regarding these 
compliance assumptions and/or derive assessments of the possible impact of poor 
compliance in the drug treatment of some disease groups. A measure of compliance can 
be developed by using an algorithm which links diagnosis, drug and dosing information. 
While some of this behaviour would not be permitted in a clinical tiial setting, poor 
utilisation patterns and poor compliance are often the norm and need to be taken into 
account when planning the design of a trial as well as in the inteipretation of trial based 
estimates of economic parameters.
This was not possible within the remit of this analysis but is possible if continuous patient 
diagnosis, drug and dosing information were linked.
While accepting databases do have a role to play in health economics research, care 
should still be taken in utilising this information. A recent CMR report (CMR, 1998)
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recently investigated the potential benefit to the pharmaceutical industry of automated 
databases in the context of health economics reseaich. They concluded automated 
databases do have relevance for health economics reseaich and could be used either alone 
or in conjunction witli other data sources but that consideration should be given to using 
different databases in a complimentary manner rather than in isolation.
They also suggest:
- allocating time and personnel to understand the unique chaiacteristics of each database.
- accessing pharmacoepidemiological skills to ensure an appropriate study design which 
controls for potential biases so as to maximise internal validity.
- expressing information needs simply to the data provider recognising that they do not 
profess to be experts in health economics.
- taking an iterative approach to study design working closely with the data providers.
- working with experts who understand automated databases.
- working with the data providers to support data developments in a way that will 
increasingly reflect health economics needs.
Willis et al (1993) suggest the following should be considered when using claims 
databases for outcomes research.
1. choosing an appropriate database
There are two major concerns in selecting a database: the patient population and the 
structure and content of the database files. The covered population must contain patients
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or cohorts of patients appropriate to the research question. It is important that the study 
population does not have unique characteristics that may affect the generalisability of the 
study findings. Characteristics such as the stability of the patient population covered by 
the plan, or the frequency of healthcare utilisation outside that covered by the plan, will 
affect the suitability of the database for outcomes reseaich. Likewise, if the patient 
population contains significant subgroups with special healthcare needs, this may skew 
the results. For example, recently insured individuals may exhibit high utilisation rates 
attributable to new access to healthcare services. If the insurance plan has a high level of 
benefits in a particular health service sector, the covered population may also have an 
inordinate level of healthcare utilisation. Health services utilisation also depends on the 
rates of illness or injury prevailing among the covered population (e.g. individuals from 
the manufacturing sector may have higher rates of accident, causing high utilisation of 
healthcare), hi general, co-payments for prescription drugs reduce the rate of dmg 
utilisation (Haiiis 1990, Leibowitz 1985, Levy 1992, Nelson 1984).
The second area of concern is the stmcture and contents of the database. A review of the 
many variables included in the database, and their definitions, should determine it’s 
content and completeness. However, while the database may list the necessary elements, 
the quality of this information must be verified, especially the way the information is 
captured by the claims processing system. A recent evaluation of a claims system showed 
it’s validity in predicting in hospital mortality, but uncovered a wide variation in 
sensitivity to nonfatal outcomes or quality of car e (lezzoni et al 1993). The ease with 
which information can be retrieved from individual files into the analytical research files
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is also critical for determining the amount of time and resources needed to conduct the 
evaluation.
Linkages among prescription drug, administration and medical and hospital databases are 
essential for developing patient-specific, longitudinal files for specific purposes 
(Hartzema 1992). The process for using these files often includes combining, or linking, 
these , several data files, resolving discrepancies and completing missing information 
(Roos 1993). In order to be linked, the files must have common data elements that 
identify unique patients or providers. For example, claims databases which identify drug 
utilisation by contract holder (i.e. those which combine all family utilisation under the 
name of one insured member) could not support a study on patient-specific episodes of 
care.
Linkages with other databases are the key to enlarging the scope of the research to allow 
additional hypothesis testing. For example, if patient zip code information in an 
administrative file is linked with census data files, the researcher would also have access 
to information about the patient’s socio-economic status.
2. Evaluating the completeness and validity of the database.
When a claims database is used for outcomes research, the completeness and the validity 
of the database should be assessed. The procedures for reimbursement of services and 
documentation of the claims will affect the integrity of the database. Where claims must 
be submitted for reimbursement, the claims database generally captures the majority of
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information about patient information utilisation of healthcare, including drugs. However, 
when compensation is made through capitated plans rather than fee for service 
arrangements, the database may be less complete. For example, physician identifiers 
within a prescription drug claim database may be eiToneous since reimbursement is rarely 
affected by the accuracy of this field. The lag between the time when the service was 
supplied and when the claims information was entered into the database will also affect 
the completeness of the database. However, electronic claims submission systems for 
prescription drag claims have greatly reduced the lag time for prescription drug claim 
information.
Outcomes research usually requires use of original patient data either to validate claims 
data or to obtain additional information (Anagaran 1991, Grady 1992, Lohr 1990, Strom 
1991). Claims databases are currently designed to record information about drag 
utilisation but not the effects of this utilisation on the patient. For example, a database 
will report the prescribed medication but will not indicate the degree the prescribed 
medication but will not indicate the degree of efficacy or adverse effects. As a result, 
additional data, such as medical chart information, is often necessary to determine the 
results associated with drag utilisation, severity of illness and the rationale behind 
changes in medication prescribing.
The data should be checked for internal validity. It must be established whether the data 
make sense given what is known from clinical experience or from other research or
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reports. Diagnostic data may be verified by checking the occuiTence of laboratory tests or 
prescription of medications that ar e unique to the specific diagnosis (Roos et al 1993). 
Diagnostic information may also be verified by comparing the database information with 
information from medical charts or a disease registry. Another useful method of cross 
checking is to compare physician inpatient service claims with institutional hospital 
claims.
3. Identification of confounding factors
The outcomes researcher must identify the factors in the claims database that can 
influence the generalisability of the findings. Insurance coverage and inclusion in a claims 
database affect healthcar e utilisation, thereby skewing any generalisation of claims data 
research to the iminsured population (Hafner-Eaton 1993). Multiple options for insurance 
produce multiple factors that may each affect healthcare utilisation (Garfinkel 1986).
Determining the clinical condition of the patient is often confounded by the difficulty in 
capturing accurate diagnostic and procedural information. Co-morbidity and 
complications can be assessed from claims databases that collect multiple diagnoses and 
multiple procedures for each claim.
Geography is another common confounding factor. Regional database information is not 
always appropriate for national studies since there are regional variations in healthcare 
utilisation, practice patterns or malpractice rates (Localio 1993, Mendenhall 1984, Welch 
1993). Since charges and/or payments vary across countries, US states, healthcare settings
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and providers, the data must be adjusted before comparisons can be made among 
prescription or healthcare costs obtained from different regions. In addition, the degree of 
patient adherence to drug therapy can be a confounding factor since the records do not 
show if a medicine has been consumed.
4. Other considerations
When claims data are used for economic analysis the issue of identifying and measuring 
healthcare costs is an important consideration. Claims data typically show billed charges 
and payment amounts but not costs or resources consumed. Cost accounting methods 
could be used to determine the costs of services for an economic analysis. However, since 
few institutions have mechanisms for determining the true costs associated with the 
provision of care, proxies for costs, such as charges or payments, are often used. Charges 
could be converted into costs by using recognised cost to charge ratios such as those used 
for the Medicare system, although the extent to which derived costs reflect true costs is 
questionable.
Research using insurance claims databases also requires that patient confidentiality be 
preserved. This requirement is often accomplished by removing patient names.
Generally, the aim of any health economic evaluation is to select from a range of 
treatment alternatives. The basic steps in any evaluation are:
1) identification of the issue to be addressed, including selection of perspective.
2) selection of competing therapies
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3) selection of evaluation of technique
4) design of study including:
- data to be collected
- patient group to be studied (inclusion criteria)
- time horizon of analysis
- sources(s) of data
4) collection of data on costs and outcomes associated with each therapy.
5) analysis of results
6) inteipretation and recommendations based on results.
Cleaiiy there is significant overlap between this process, the suggestions put forward by 
Lair and the otitis media analysis; any method that contributes information to this process 
will be useful in conducting a phaimacoeconomic analysis paiticularly in highlighting 
relevant comparators, endpoints, sample size, relevant patient sub-groups and study time 
horizons.
However, the role of databases should not only be focused on assisting individual study 
design. The database used in this analysis could certainly have been used to look at 
a number of broader outcomes research questions, beyond otitis media and beyond just 
the outcomes associated with pharmaceuticals, such as:
- the total costs incurred, for each HMO, for all diseases and treatments and breaking 
them down into program budgets to see how and where each HMO spends i f  s 
resources relative to other HMOs.
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- ranking the diseases that incur most cost (on an annual or lifetime basis) to inform 
targeting decisions.
- ranking the patient subgroups which incur the most cost either in total or on a per 
patient basis (e.g. by age, sex, disease etc.).
- construction of patient flow models in order to see the paths patients taken through an 
HMO, if any bottle necks exists etc.
- examining the costs following surgical interventions.
- comparing service deliveiy patterns e.g. re-admission rates against national statistics 
for certain procedures to see, as a proxy, if any groups of patients are being 
discharged too early.
- reviewing the prescribing data to check for appropriateness of use, overuse and 
underuse.
- tiying to assess the adherence to treatment guidelines and protocols and/or predicting 
the cost effects of introducing new ones.
identifying the appropriate comparator in a phaimacoeconomic study. Most 
economic studies will want to compaie itself against the currently used treatment (in 
some countries, such as Australia, it’s required as part of the economic submission), 
hi most cases, the most commonly used alternative can be derived from the claims 
database without the need for any study.
The information databases contain can also be used to help guide broader issues of
pharmaceutical research throughout the development process. For example:
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1) generating prevalence and ‘cost-of illness’ estimates in order to assess current high 
cost, high volume disease areas
2) to understand the burden of illness in terms of incidence, progression, severity and to 
assess the economic viability of compounds in early development.
3) provide assessment of compliance in order to facilitate decisions on dosing, quality of 
drug consumption, new drug formulations etc.
4) give assessments of the extent of adverse event issues with current treatments.
5) using all of these to help guide and inform pharmaceutical research priorities.
In a UK context, we clearly don’t have the same availability of these types of insurance 
databases that so closely link financial tracking and the delivery of cai'e. A considerable 
amount of data are recorded in the course of treatment such as diagnostic and treatment 
data as well as some outcome data, which aie usually held in casenotes. The NHS 
captures enormous amount of detail but these seldom get translated into usable data. 
Casenotes in England still tend to be handwritten, specific to the site of treatment and aie 
difficult to inteipret. However, computerisation of case notes offers scope for their 
development. If it is to be turned into data then challenges do exist e.g. standardised 
coding systems would be essential, e.g. the International Classification of Disease but 
with regular updates on new diseases. However, the right sort of data does exist if only 
we could find a way of making it accessible and robust.
Possibly the neaiest databases we currently have in the UK, to the ones seen in the US, 
aie prescription databases such as DIN-LINK (The Doctors Independent Network,
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Compiifile Group, Woking UK), GPRD (General Practice Research Database, GP 
Database Research Company, London UK) and MEDIPLIUS (M S UK Ltd, London UK) 
along with MEMO (Tayside Medicines Monitoring Unit, University of Dundee, Scotland) 
that attempts to track all forms of care. GPRD and MEMO were set up primarily to 
provide supplementary sources of data for the evaluation of drag safety, DIN-LINK and 
MEDIPLUS to provide information to support the marketing of pharmaceuticals. 
However, these have been criticised (CMR Report 1997) for:
- being complex and difficult to access the required information.
- the outputs depending on the skill of the operator.
- insufficient level of detail on outcomes.
- other than MEMO there is insufficient detail on secondaiy care activity
- representativeness, MEMO is largely restricted to Tayside (for secondary care data)
whilst the others encompass less than 12% of the total population of the UK
Clearly, what is required in the UK are databases of a broader nature than we currently 
possess and more in line with what we see in the US (but ideally possessing more 
‘outcome’ data than they currently do). This would enable all of those involved in the 
delivery of care to assess how that care is delivered in the UK and how appropriate it 
actually is. Given the increased emphasis on cost contiol in the NHS, this is more likely 
than ever going to drive through the links between financial data and delivery of care (as 
we see in the managed care environment in the US). This may mean, especially with the 
development of IT and the NHS Net, that the time for more integrated NHS data 
collection is about to emerge. This will be vital for the pharmaceutical industry in a time
113
of constrained NHS resource, in order to track how health care is delivered, understand 
areas of unmet need and provide a baseline to highlight the value of the products it 
produces relative to cuixent care.
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5. Conclusions
Most daims databases should be able to provide the following infomiation to inform an 
economic evaluation of a medicine,
1) identifying appropriate economic endpoints.
2) defining the patterns of usual care and spectrum of current therapy.
3) determining episode duration.
4) highlighting adverse events.
5) determining sample size for economic endpoints.
6) identifying important economic stratifying variables.
7) quantifying compliance expectations.
However, the data held by claims databases can also be used to guide the wider research 
agenda. For example:
1) confirming prevalence and incidence rates to validate internal estimates.
2) deriving direct cost of illness estimates so an understanding can be gained of the 
impact imposed by the disease.
3) deriving progression and severity rates with cost estimates to assess the economic 
viability of compounds in early development.
4) providing assessment of compliance with cunent treatments. This could inform future 
decisions about a products dosing etc.
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5) giving assessments of the extent of adverse event issues with current treatments,
6) using all of these to help derive economic analyses of current treatments.
In both cases, the following should be considered when a database is chosen for any 
economic assessment.
1) does the database hold a cohort of patients appropriate to the disease?
2) is the database completed both fully and accurately?
3) are there any confounding factors in the data that will influence the generalisability of 
the findings?
On the basis of the research contained in this dissertation, we would put forward the 
ai'gument that the infoimation that can be obtained from health care databases has an 
invaluable role in guiding the design of economic studies conducted by the 
pharmaceutical industry. Furthermore, the use of this information in steering the reseaich 
agenda, should also be emphasised. -
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7. Figures
Figure 1- Claims by month
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Figure 3a - % of episodes with initiating antibiotics - acute OM, all HMOs
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Figure 4a - % of episodes with initiating antibiotics - Acute OM, HMOl
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Figure 5a - % of episodes with initiating antibiotics - acute OM, HM02
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Figure 6a - % of episodes with initiating antibiotics - acute OM, HM03
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Figure 7 - Costs associated with the diagnosis and treatment of otitis media
All otitis media cases combined
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Figure 8b - costs associated with the diagnosis and treatment of otitis media
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8. Tables
Table 1 - otitis media claims origination
Plan 07/01/92- 01/01/93- 07/01/93- 01/01/94- Plan total
H 12/31/92 06/30/93 12/31/93 06/30/94
HMOl Dr: 8721 
HI: 2062
Dr: 9495 
HI: 2179
Dr: 7879 
HI: 1769
Dr: 10,697 
HI: 2414
Dr: 36,792 
HL: 8424 
45,216
HM02 Dr: 12,791 
HI: 2272
Dr: 18,668 
HI: 3070
Dr: 14,162 
HI: 2092
Dr: 21,569 
HI: 3597
Dr: 67,190 
HI: 11,031 
78,221
HM03 Dr: 4746 
HI: 649
Dr: 7273 
HI: 1436
Dr: 6053 
HI: 1146
Dr: 10,175 
HI: 1917
Dr: 28,247 
HI: 5148 
33,395
Total Dr: 26,258 
HI: 4983
Dr: 35,436 
HI: 6685
Dr: 28,094 
HI: 5007
Dr: 42,441 
HI: 7928
Dr: 132,229 
HI: 24,603 
156,832
No. of doctor claims
No. of hospital/facility claims
Table 2 - Otitis media prevalence rates - study population 
Ail otitis media codes combined
Plan group
<1 1 2 3 4 5 6 Total
HMOl 219 433 312 253 223 201 201 1842
810 576 410 395 455 479 505 3630
270 752 761 641 490 420 398 507
HM02 459 946 866 676 592 563 539 4641
1852 1331 1090 1007 1011 1010 1086 8387
248 710 794 671 586 557 496 553
HM03 269 409 235 156 164 147 539 1484
964 514 289 244 273 278 1086 2788
279 796 813 639 601 529 496 532
Total 947 1788 1413 1085 979 911 844 7967
3626 2421 1789 1646 1739 1767 1817 14805
261 739 790 659 563 516 465 538
otitis media cases
No. continuously enrolled
Rate per 100
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Table 3 - otitis media prevalence rates - all otitis media episodes combined (males)
Plan grotip
<1 1 2 3 4 5 6 Total
HMOl 110 227 162 144 123 110 113 989
403 302 209 222 248 254 272 1910
273 752 775 649 496 433 415 518
HM02 248 511 436 343 305 291 266 2400
936 691 543 509 511 505 555 4250
265 740 803 674 597 576 479 565
HM03 150 217 134 76 85 89 43 794
486 269 154 124 130 150 105 1418
309 807 870 613 654 593 410 560
Total 508 955 732 563 513 490 422 4183
1825 1262 906 855 889 909 932 7578
278 757 808 658 577 539 453 552
otitis media cases
No. continuously enrolled
Rate per 100
Table 4 - otitis media prevalence rates - all otitis media episodes combined (females)
Plan group
<1 1 2 3 4 5 6 Total
HMOl 109 206 150 109 100 91 88 853
407 274 201 173 207 225 233 1720
268 752 746 630 483 404 378 496
HM02 211 435 430 333 287 272 273 2241
916 640 547 498 500 505 531 4137
230 680 786 669 574 539 514 542
HM03 119 192 101 80 79 58 61 690
478 245 135 120 143 128 121 1370
249 784 748 666 552 453 504 504
Total 439 833 681 522 466 421 422 3784
1801 1159 883 791 850 858 885 7227
244 719 771 660 548 491 477 524
otitis media cases
No. continuously enrolled
Rate per 100
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Table 5 - Acute or chronic assignment.
Plan Gender Acute otitis 
media
Chronic otitis 
media
Total
HMOl Male 450 539 989
Female 422 431 853
Total 872 970 1842
Percent mems 47 53
HM02 Male 1205 1195 2400
Female 1179 1062 2241
Total 2384 2257 4641
Percent mems 51 49
HM03 Male 343 451 794
Female 371 319 690
Total 714 770 1484
Percent mems 48 52
All HMOs Male 1998 2185 4183
Female 1972 1812 3784
Total 3970 3997 7967
Percent mems 50 50
Number of males assigned 
Number of females assigned 
Total number of members assigned 
Percent of members assigned
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Table 6 - chronic otitis media assignment
Plan Assignment definition Prior year 
No, assigned
Study period 
No. assigned
Total
HMOl ICD - 9 code 114 111 225
Episode>30 days 20 82 102
Drug therapy>30 days 118 291 409
Tympanostomy tubes 10 9 19
3+ acute episodes 77 138 215
Plan total 339 631 970
HM02 ICD - 9 code 168 271 439
Episode>30 days 52 211 263
Drug therapy>30 days 356 724 1080
Tympanostomy tubes 16 6 22
3+ acute episodes 179 274 453
Plan total 771 1486 2257
HM03 ICD - 9 code 23 68 91
Episode>30 days 12 59 71
Drug therapy>30 days 146 290 436
Tympanostomy tubes 13 6 19
3+ acute episodes 56 97 153
Plan total 250 520 770
ALL ICD - 9 code 305 450 755
HMOs Episode>30 days 84 352 436
Drug therapy>30 days 620 1305 1925
Tympanostomy tubes 39 21 60
3+ acute episodes 312 509 821
Plan total 1360 2637 3997
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Table 12 - Tympanostomy tube insertions
Plan Gender No» members 
with chronic 
otitis media
No» members 
with tymp. 
tubes
% members 
with tymp tubes
HMOl Male 539 139 26
Female 431 100 23
Total 970 239 25
HM02 Male 1195 217 18
Female 1062 151 14
Total 2257 368 16
HM03 Male 451 97 22
Female 319 67 21
Total 770 164 21
Male 2185 453 21
Total Female 1812 318 18
Total 3997 771 19
Table 13 - Adenoidectomy procedures
Plan Gender No. members 
with chronic 
otitis media
No. members 
with ad. 
edctomy
% members 
with ad ectomy
HMOl Male 539 70 13
Female 431 44 10
Total 970 114 12
HM02 Male 1195 117 10
Female 1062 93 9
Total 2257 210 9
HM03 Male 451 64 14
Female 319 46 14
Total 770 110 14
Male 2185 251 11
Total Female 1812 183 10
Total 3997 434 11
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Table 14 - episodes o: otitis media.
Plad Episode
Type
No» of episodes Average no. of days 
in episode
HMOl Dx 824 1
Dx-Dx 1404 30
Dx-Rx 1974 23
Rx-Dx 71 20
Rx-Rx 34 44
All episodes 4307
HM02 Dx 1988 1
Dx-Dx 3150 29
Dx-Rx 5394 21
Rx-Dx 162 24
Rx-Rx 80 41
All episodes 10774
HM03 Dx 576 1
Dx-Dx 946 33
Dx-Rx 1704 26
Rx-Dx 56 19
Rx-Rx 34 47
All episodes 3316
Total Dx 3388 1
Dx-Dx 5500 30
Dx-Rx 9072 22
Rx-Dx 289 22
Rx-Rx 148 43
All episodes 18397
Table 15 - Office visits per episode
Plan Number of visits
4+ Total
HMOl 202 2376 937 333 459 4307
5 55 22 8 11
HM02 440 6552 2189 783 810 10774
4 61 20 7 8
HM03 99 1856 723 300 338 3316
3 56 22 9 10
All HMOs 741 10784 3849 1416 1607 18397
4 59 21 8 9
Number of episodes 
Per cent of episodes
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Table 16 - Initiating antibiotic within otitis media episodes
Plan Initiating
antibiotic
Acute otitis 
No» episodes % episodes
Chronic 
otitis media
No. episodes % episodes
HMOl None 580 43 822 28
Amoxycillin 342 25 675 23
Amox/Clav 83 6 348 12
Cefaclor 114 8 396 13
Other ceph 80 6 2971 10
Other 160 12 410 14
HM02 None 1011 27 2033 29
Amoxycillin 1921 52 2543 36
Amox/Clav 229 6 760 11
Cefaclor 166 4 540 8
Other ceph 158 4 476 7
Other 217 6 720 10
HM03 None 308 28 506 23
Amoxycillin 516 47 719 32
Amox/Clav 53 5 166 7
Cefaclor 74 7 314 14
Other ceph 21 2 117 5
Other 122 11 400 18
Total None 1899 31 3361 27
Amoxycillin 2779 45 3937 32
Amox/Clav 365 6 1274 10
Cefaclor 354 6 1250 10
Other ceph 259 4 890 7
Other 499 8 1530 12
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Table 17 - Frequency of prescribed therapy
Plan Frequency
prescribed
therapy : Amox/clln Augmentin
1st
; andbiotic 
Cefaclor y.- % Other
HMOl IRx 682 243 300 219 354
2Rx 172 101 105 70 103
3+Rxs 163 87 105 88 113
HM02 IRx 3135 562 441 375 545
2Rx 767 197 129 127 219
3+Rxs 562 230 136 132 173
HM03 IRx 759 120 206 70 305
2Rx 255 41 77 26 102
3+Rxs 221 58 105 42 115
All HMOs IRx 4576 925 947 664 1204
2Rx 1194 339 311 223 424
3+Rxs 946 375 346 262 401
Table 18 - Suppurative vs non-suppurative otitis media diagnosis and treatment
Plan Otitis
category
No anti­
biotic 
treatmen
Number
Anti­
biotic
treatmen
t
Number
1 Total 
number
HMOl Non-s 352 25 675 23 1027 24
Supp 200 14 501 17 701 16
Unspec 850 61 1729 60 2579 60
HM02 Non-s 903 30 893 12 1796 17
Supp 552 18 2077 27 2629 24
Unspec 1589 52 4760 62 6349 59
HM03 Non-s 209 26 310 12 519 16
Supp 240 29 874 35 1114 33
Unspec 365 45 1318 53 1683 51
All Non-s 1464 28 1878 14 3342 18
HMOs Supp 992 19 3452 26 4444 24
Unspec 2804 53 7807 59 10611 58
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Table 19 - Antibiotic therapy during an episode and presence of tympanostomy tubes
Plan Drug therapy No tubes 
present
Tubes present Total
HMOl No antibiotic 1248 154 1402
Antibiotic 2669 236 2905
HM02 No antibiotic 2541 503 3044
Antibiotic 7366 364 7730
HM03 No antibiotic 694 120 814
Antibiotic 2316 186 2502
All HMOs No antibiotic 4483 111 5260
Antibiotic 12351 786 13137
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Table 20 - annual and study period costs associated with the treatment of otitis media - all
otitis media cases combined
Plan Treatment Physician 
outpatient 
services :
Emergenc
services
inpatient
hosp.
drugs Total costs
HMOl 7/92-6/92 1048 102 2 856 1048272,358 17,269 4177 46,669 340,473
260 169 2088 55 325
80% 5% 1% 14%
7/93-6/94 1361 154 8 1083 1361
345,033 26,964 42,606 66,325 480,929
254 175 5326 61 353
72% 6% 9% 14%
Study 1842 241 10 1469 1842
Period 617,391 44,233 46,783 112,995 821,402
335 184 4678 77 446
75% 5% 6% 14%
HM02 7/92-6/92 2743 227 18 2320 2743443,169 35,558 34,510 92,770 606,008
162 157 1917 40 221
73% 6% 6% 15%
7/93-6/94 3470 255 23 2930 3470
527,673 42,191 63,899 124,804 758,567
152 165 2778 43 219
70% 6% 8% 16%
Study 4641 459 39 3975 4641
Period 970,842 77,749 98,410 217,574 1,364,575
209 169 2523 55 294
71% 6% 7% 16%
HM03 7/92-6/92 775 58 7 669 775171,293 12,402 15,260 32,648 231,603
221 214 2180 49 300
74% 5% 7% 14%
7/93-6/94 1177 84 12 995 1177
218,046 12,402 39,562 49,143 327,239
185 214 3297 49 278
67% 5% 12% 15%
Study 1484 132 19 1290 1484
Period 389,340 32,890 54,822 81,791 558,842
262 249 2885 3845 377
70% 6% 10% 15%
All HMOs 7/92-6/92 4566 387 27 3845 4566886,820 65,229 53,947 172,087 1,178,084
194 169 1998 45 258
75% 5% 5% 15%
7/93-6/94 6008 493 43 5008 6008
1,090,753 89,643 146,067 240,272 1,566,735
182 182 3397 48 261
70% 6% 9% 15%
Study 7967 832 68 6734 7967
Period 1,977,573 154,872 200,015 412,360 2,744,819
248 186 2941 48 345
72% 6% 7% 15%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table 21 - annual and study period costs associated with the treatment of otitis media -
acute otitis media cases
Plan Treatment
period
Physician
outpatient
Emergenc inpatient
hosp.
drugs Total costs
HMOl 7/92-6/92 382 42 0 283 38221,887 7055 0 6127 35,069
57 168 0 22 92
62% 20% 0% 17%
7/93-6/94 569 64 5 392 569
38,484 10,067 15,465 9489 73,504
68 157 3093 24 129
52% 14% 21% 13%
Study 872 103 5 589 872
Peiiod 60,371 17,122 15,465 15,616 108,573
69 166 3093 27 125
56% 16% 14% 14%
HM02 7/92-6/92 1143 87 7 947 114365,580 13,073 11,105 14,292 104,050
57 150 1586 15 91
63% 12% 11% 14%
7/93-6/94 1591 112 8 1283 1591
89,959 17,689 22,187 20,979 150,814
57 158 2773 16 95
60% 12% 15% 14%
Study 2384 195 15 1914 2384
Period 155,540 30,762 33,292 35,271 150,814
65 158 2219 18 63
61% 12% 13% 14%
HM03 7/92-6/92 275 20 1 220 27515,006 3698 950 3759 23,413
55 185 950 17 85
64% 16% 4% 16%
7/93-6/94 540 30 3 425 540
30,754 6632 12,394 7034 56,815
57 221 4131 17 105
54% 12% 22% 12%
Study 714 49 4 561 714
Period 45,761 10,330 13,344 10,793 80,228
64 211 3336 19 112
57% 13% 17% 13%
All HMOs 7/92-6/92 1803 149 8 1450 1803102,473 23,826 12,055 24,178 162,532
57 160 1507 17 90
63% 13% 7% 15%
7/93-6/94 2697 206 16 2100 2697
159,198 34,387 50,046 37,502 281,133
59 167 3128 18 104
57% 12% 18% 13%
Study 3970 347 24 3064 3970
Period 261,671 58,213 62,101 61,680 443,665
66 168 2588 20 112
59% 13% 14% 14%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table 22 - annual and study period costs associated with the treatment of otitis media -
chronic otitis media cases
Plan Treatment Physiciari
outpatient
services
Emergenc inpatient
hosp.
drugs Total costs
HMOl 7/92-6/92 666 60 2 573 666
250,471 10,214 4177 40,543 305,405
376 170 2088 71 459
82% 3% 1% 13%
7/93-6/94 792 90 3 691 792
306,549 16,897 27,141 56,836 407,424
387 188 9047 82 514
75% 4% 7% 14%
Study 970 138 5 880 970
Period 557,020 27,111 31,318 97,379 712,829
574 196 6264 111 735
78% 4% 4% 14%
HM02 7/92-6/92 1600 140 11 1373 1600
377,589 22,485 23,406 78,478 501,957
236 161 2128 57 314
75% 4% 5% 16%
7/93-6/94 1879 143 15 1647 1879
437,714 24,502 41,712 103,825 607,753
233 171 2781 63 323
72% 4% 7% 17%
Study 2257 264 24 2061 2257
Period 815,303 46,987 65,117 182,303 1,109,711
361 178 2713 88 492
73% 4% 6% 16%
HM03 7/92-6/92 500 38 6 449 500
156,287 8704 14310 28,889 208,190
313 229 2385 64 416
75% 4% 7% 14%
7/93-6/94 637 54 9 570 637
187,292 13,856 27,168 42,109 270,425
295 257 3019 74 425
69% 5% 10% 16%
Study 770 83 15 729 770
Period 343,579 22,560 41,478 70,997 478,615
446 272 2765 97 622
72% 5% 9% 15%
All HMOs 7/92-6/92 2766 238 19 2395 2766
784,347 41,403 41,893 147,909 1,015,552
284 174 2205 62 367
77% 4% 4% 15%
7/93-6/94 3308 287 27 2980 2766
931,555 55,256 96,021 202,771 1,015,552
282 193 3556 70 367
72% 4% 77% 16%
Study 3997 485 44 3670 3997
Period 1,715,902 96,659 137,914 350,680 2,301,154
429 199 3134 96 576
75% 4% 6% 15%
Number of members
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table 23 - costs associated with the treatment of otitis media by initiating antibiotic
All HMOs combined
Plan Initiating
antibiotic
Physician
outpatient
services
Emergenc
0sermceS:ix::
inpatient
hosp.
Total costs
All HMOs None 5007 256 16 126 5260
371,764 39,182 43,511 1088 455,545
74 153 2719 9 87
82% 9% 10% 0%
Amoxycill 6489 352 24 6716 6716
in 610,970 53,275 62,133 117,700 844,078
94 151 25M 18 126
72% 6% 7% 14%
Amoxycill 1610 82 10 1639 1639
in/clavula 232,706 14,834 19,670 85,926 353,136
nate 145 181 1967 52 215
66% 4% 6% 24%
Cefaclor 1132 130 7 1604 1604
188,393 24,914 28^#3 85,901 409,802
166 192 4069 54 255
68% 6% 7% 21%
Other 1969 42 7 1149 1149
ceph 303,236 6476 18,665 65,176 278,710
154 154 2666 57 243
75% 2% 7% 23%
Any other 1969 104 8 2029 2029
antibiotic 303,236 16,192 27,552 56,569 403,549
154 156 3444 28 199
75% 4% 7% 14%
Total 17,746 966 72 13,263 18,397
1,977,573 154,872 200,015 412,360 2,744,820
111 160 2778 31 149
72% 6% 7% 15%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table 24 - costs associated with the treatment of otitis media by initiating antibiotic
All HMOs combined
Plan Initiating
antibiotic
Physician
outpatient
services
Emergenc
services
inpatidnt drugs Total costs
All HMOs None 1752 146 7 46 1899
74,735 23,464 11,120 343 109,682
43 161 1589 7 58
68% 21% 10% 0%
Amoxycill 2641 145 11 2779 2779
in 119,787 19,329 29,809 22,125 191,050
45 133 2710 8 69
63% 10% 16% 12%
Amoxycill 347 19 2 365 365
in/clavula 17,107 3577 4338 11,791 36,813
nate 49 188 2169 32 101
46% 10% 12% 32%
Cefaclor 323 34 3 354 354
15,997 5980 15,322 12,477 49,776
50 176 5107 35 141
32% 12% 31% 25%
Other 250 9 1 259 259
ceph 12,049 1513 1512 8694 23,768
48 168 1512 34 92
51% 6% 6% 37%
Any other 470 31 0 499 499
antibiotic 21,997 4350 0 6250 32,597
47 140 0 13 65
67% 13% 0% 19%
Total 5783 384 24 4302 6155
261,671 58,213 62,101 61,680 443,665
45 152 2588 14 72
59% 13% 14% 14%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table 25 - costs associated with the treatment of otitis media by initiating antibiotic
All HMOs combined
Plan Initiating
antibiotic
Physician
outpatient
services
Emergenc
services
inpatient drugs Total costs
All HMOs None 3255 110 9 80 3361
297,029 15,718 32,391 745 345,883
91 143 3599 9 103
86% 5% 10% 0%
Amoxycill 3848 207 13 3937 3937
in 491,183 33,946 32324 95,575 653,028
128 164 2486 24 166
75% 5% 5% 15%
Amoxycill 1263 63 8 1274 1274
in/clavula 215,600 11,257 15,332 74,135 316,324
nate 171 179 1917 58 248
68% 4% 5% 23%
Cefaclor 1216 96 4 1250 1250
254,507 18,934 13,162 73,424 360,027
209 197 3290 59 288
71% 5% 4% 20%
Other 882 33 6 890 890
ceph 176,345 4963 17,153 56,481 254,942
200 150 2859 63 242
71% 2% 7% 22%
Any other 1499 73 8 1530 1530
antibiotic 281,239 11,842 27,552 50,319 370,952
188 162 3444 33 242
76% 3% 7% 14%
Total 11,963 582 48 8961 12,242
1,175,902 96,659 137,914 350,680 2,301,155
143 166 2873 39 188
75% 4% 6% 15%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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9. Appendix I - costs associated with the treatment of otitis media episodes.
Table I-I - costs associated with the treatment of otitis media by initiating antibiotic
HMOl
Plan Initiating
antibiotic
Physician
outpatient
services
Emergenc
services
inpatient
hosp.
Total costs
HMO 1 None 1320 90 4 44 1402
114,736 13,455 16,238 445 144,874
87 149 4059 10 103
79% 10% 11% 0%
Amoxycill 991 51 1 1017 1017
in 129,048 6914 2074 22,375 160,411
130 136 2074 22 158
81% 4% 1% 14%
Amoxycill 417 32 1 431 431
in/clavula 68,722 5914 1000 23,003 98,6#
nate 165 185 1000 53 229
70% 6% 1% 23%
Cefaclor 493 41 1 510 510
110,095 9210 7310 28,538 155,153
223 225 7310 56 304
71% 6% 5% 18%
Other 371 14 1 377 377
ceph 87,224 2406 1512 21,774 112,916
235 172 1512 58 300
77% 2% 1% 20%
Any other 542 45 3 570 570
antibiotic 107,566 6333 18,649 16,859 149,407
198 141 6216 30 262
72% 4% 13% 11%
Total 4134 273 11 2949 4307
617,391 44,233 46,783 112,995 821,402
149 162 4253 38 191
75% 5% 6% 14%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
151
Table 1-2 - costs associated with the treatment of otitis media by initiating antibiotic
HMOl
Plan Initiating
antibiotic
Physician
outpatient
Emergenc
y
services
inpatient
:hosp.
drugs Total costs
HMOl None 527 55 2 18 580
23,767 8305 4568 165 36,805
45 151 2284 9 63
65% 23% 12% 0%
Amoxycill 326 16 1 342 342
in 16,000 1815 2074 3110 22,999
49 113 2074 9 67
70% 8% 9% 13%
Amoxycill 73 12 0 83 83
in/clavula 3584 2470 0 3127 9181
nate 49 206 0 38 111
39% 27% 0% 34%
Cefaclor 104 10 1 114 114
5765 2095 7310 4156 19,326
55 210 7310 36 170
30% 11% 38% 21%
Other 77 2 1 80 80
ceph 4172 235 1512 2599 8518
54 118 1512 32 106
49% 3% 18% 30%
Any other 144 18 0 160 160
antibiotic 7082 2200 0 2458 11,740
49 122 0 15 73
60% 19% 0% 21%
Total 1251 113 5 797 1359
60,371 17,122 15,465 15,616 108,574
48 152 3093 20 80
56% 16% 14% 14%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table 1-3 - Costs associated with the treatment of otitis media by initiating antibiotic
HMOl
Plan Initiating
antibiotic
Physician
outpatient
Emergenc inpatient
hosp.
drugs Total costs
HMO 1 None 793 35 2 26 822
90,969 5149 11,669 280 108,067
115 147 5835 11 131
84% 5% 11% 0%
Amoxycill 665 35 0 675 675
in 113,048 5099 0 19,265 137,412
170 146 0 29 204
82% 4% 0% 14%
Amoxycill 344 20 1 348 348
in/clavula 65,138 3444 1000 19,876 89^68
nate 189 172 1000 57 257
73% 4% 1% 22%
Cefaclor 389 31 0 396 396
104,330 7115 0 24J82 135,827
268 230 0 62 343
77% 5% 0% 18%
Other 294 12 0 297 297
ceph 83,052 2171 0 19,175 104,398
282 181 0 65 352
80% 2% 0% 18%
Any other 398 27 3 410 410
antibiotic 100,483 4133 18,649 14,401 137,666
252 153 6216 35 336
73% 3% 13% 11%
Total 2#83 160 6 2152 2848
557,020 27,111 31,318 97,379 712,828
193 169 5220 45 242
78% 4% 4% 14%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table 1-4 costs associated with the treatment of otitis media by initiating antibiotic
HM02
Plan Initiating . 
antibiotic
Physician
outpatient
services
Emergenc
services
inpatient
hosp.
î;drup:--^ v^:::-;: Total costs
HMO 2 None 2916 118 8 69 3044
202,171 16,493 13,741 532 232,937
69 140 1718 8 77
87% 7% 6% 0%
Amoxycill 4281 255 16 4464 4464
in 347,159 37,105 37,372 70,970 492,606
81 146 2336 16 110
71% 7% 8% 14%
Amoxycill 977 37 7 989 989
in/clavula 128,330 6208 14,597 50,872 200,007
nate 131 168 2085 51 202
64% 3% 7% 25%
Cefaclor 664 60 2 706 706
92,058 6208 9106 36,018 145,118
139 168 4553 51 206
63 3% 6% 26%
Other 623 26 6 634 634
ceph 79,178 3574 17,153 34,178 134,083
127 137 2859 54 211
59% 3% 13% 25%
Any other 912 42 3 937 937
antibiotic 121,945 6433 6440 25,003 159,821
134 153 2147 27 171
76% 4% 4% 16%
Total 10,373 538 42 7799 10,744
970,842 77,749 98,410 217,574 1,364,575
94 145 2343 28 127
71% 6% 7% 16%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table I- 5 Costs associated with the treatment of otitis media by initiating antibiotic
HM02
Plan; Initiating
antibiotic
# 0 0 0 #
outpatient
: serviW::! :
Emergent
services
Total costs
HMO 2 None 943 65 4 26 1011
39J95 9988 5601 153 55,137
42 154 1400 6 55
72% 18% 10% 0%
Amoxycill 1810 112 8 1921 1921
in 81,011 14,522 20,384 14,789 130,706
45 130 2548 8 68
62% 11% 16% 11%
Amoxycill 221 6 2 229 229
in/clavula 10,997 867 4338 6867 1&,896
nate 50 145 2169 30 114
47% 4% 19% 29%
Cefaclor 146 22 1 166 166
7049 3350 2969 5528 18^86
48 152 2969 33 114
37% 18% 16% 29%
Other 152 6 0 158 158
ceph 6876 1063 0 5431 13,370
45 177 0 34 85
51% 8% 0% 41%
Any other 208 7 0 217 217
antibiotic 10,212 973 0 2502 13,687
49 139 0 12 63
75% 7% 0% 18%
Total 3480 218 15 2717 3702
155,540 30,762 33,292 35,271 254,865
45 141 2219 13 69
61% 12% 13% 14%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table I- 6 Costs associated with the treatment of otitis media by initiating antibiotic
HM02
Chronic Otitis Media Episodes
Plan Initiating Physician Emergenc inpatient drugs Total costs
antibiotic outpatient
services yservices
hosp.
HMO 2 None 1973 53 4 43 2033
162,776 6505 8140 379 177,808
83 123 2035 9 87
91% 4% 5% 9%
Amoxycill 2471 143 8 2543 2543
in 266,148 22,584 16,988 56,180 361,900
108 158 2123 22 142
73% 6% 5% 16%
Amoxycill 756 31 5 760 760
in/clavula 117,333 5341 10,259 44,005 176,938
nate 155 172 2052 58 233
66% 3% 6% 25%
Cefaclor 518 38 1 540 540
85,010 4586 6137 30,490 126,223
164 121 6137 56 234
67% 4% 5% 24%
Other 471 20 6 476 476
ceph 72,303 2511 17,153 28,747 120,714
154 126 2899 60 254
60% 2% 4% 24%
Any other 704 35 3 720 720
antibiotic 111,733 5460 6440 22,501 146,134
159 156 2147 31 203
77% 4% 4% 15%
Total 6893 320 27 5082 7072
815,303 46,987 65,117 182,303 1,109,710
118 147 2412 36 157
74% 4% 6% 16%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table I- 7 Costs associated with the treatment of otitis media by initiating antibiotic
HM03
Plan Initiating
antibiotic
Physician
outpatient
Emergenc
y
services
inpatient
hosp.
drugs Total costs
HMO 3 None 771 48 4 13 814
54,857 9234 13,532 110 77,733
71 192 3383 8 95
71% 12% 17% 0%
Amoxycill 1217 46 7 1235 1235
in 134,762 9255 22,687 24,355 54,489
165 201 3241 20 249
65% 5% 12% 13%
Amoxycill 216 13 2 219 219
in/clavula 35,654 2711 4073 12,051 54,489
nate 165 209 2036 55 249
65% 5% 8% 22%
Cefaclor 382 29 4 388 388
68,350 7768 12,067 21,345 31,710
179 268 3017 55 230
62% 7% 11% 20%
Other 138 2 0 138 138
ceph 21,991 496 0 9223 31,710
159 248 0 67 230
69% 2% 0% 29%
Any other 515 17 2 522 522
antibiotic 73,725 3426 2462 14,707 94,320
143 202 1231 28 181
78% 4% 3% 15%
Total 3239 155 19 2515 3316
389,340 32,890 54,822 81,791 558,843
120 212 2885 33 169
70% 6% 10% 14%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table I- 8 Costs associated with the treatment of otitis media by initiating antibiotic
HM03
Plan Initiating
antibiotic
Physician
outpatient
services
Emergenc
yservices
inpatient drugs Total costs
HMO 3 None 282 26 1 2 308
11,573 5171 950 25 17,719
41 199 950 12 58
65% 29% 6% 0%
Amoxycill 505 17 2 516 516
in 22,776 2992 7351 4225 4561
45 176 3675 8 86
61% 8% 20% 11%
Amoxycill 53 1 0 53 53
in/clavula 2525 240 0 1796 4561
nate 48 240 0 34 86
56% 5% 0% 39%
Cefaclor 73 2 1 74 74
3183 535 5043 2793 11,554
44 268 5043 38 156
27% 5% 44% 24%
Other 21 1 0 21 21
ceph 1001 215 0 664 1880
48 215 0 32 90
53% 12% 0% 35%
Any other 118 6 0 122 122
antibiotic 4702 1177 0 1291 7170
40 196 0 11 59
66% 16% 0% 18%
Total 1052 53 4 788 1094
45,761 10,330 13,344 10,793 80,228
43 195 3336 14 73
57% 13% 17% 13%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table I- 9 Costs associated with the treatment of otitis media by initiating antibiotic
HM03
Plan Initiating
antibiotic
Physician
outpatient
services
Emergenc
yservices
inpatient
hosp.
drugs Total costs
HMO 3 None 489 22 3 11 506
43,284 4063 12,582 86 60,015
89 185 4194 8 119
72% 7% 21% 0%
Amoxycill 712 29 5 719 719
in 111,986 6263 155,336 20,130 153,715
157 216 3067 28 214
73% 4% 10% 13%
Amoxycill 163 12 2 166 166
in/clavula 33,129 2471 4073 10,255 49,928
nate 203 206 2036 62 301
66% 5% 8% 21%
Cefaclor 309 27 3 314 314
65,167 7233 7024 18,255 97,976
211 268 2341 62 312
67% 7% 7% 21%
Other 117 1 0 117 117
ceph 20,990 281 0 8559 29,830
179 281 0 73 255
70% 1% 0% 29%
Any other 397 11 2 400 400
antibiotic 69,023 281 2462 13,417 87,151
174 281 1231 34 218
79% 1% 3% 15%
Total 2187 102 15 1727 2222
343,579 22,560 41,478 70,997 478,614
157 221 2765 41 215
72% 5% 8% 15%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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10. Appendix II - statistical analyses members with otitis media
Table II I Chi-square analysis, otitis media diagnosis by plan
Plan Otitis media
Yes No
HMOl 1842 1788 3630
(1953) (1677)
HM02 4641 3746 8387
(4513) (3874)
HM03 1484 1304 2788
(1500) (1288)
7967 6388 14,805
X^=21.9 df=2 p<0.05*
Table II-2 Chi-square analysis, otitis media diagnosis by gender
Gender Otitis media
Yes No
Male 4183 3395 7578
(4078) (3500)
Female 3784 3443 7227
(3889) (3338)
7967 6388 14,805
X^=11.9 df=l p<0.05*
Table II-3 Chi-square analysis, otitis media group by gender
Gender Yes No
Male 1998 2185 4183
(2084) (2099)
Female 1972 1812 37&4
(1886) (1898)
3970 3997 7967
X%=14.9 df=l p<0.05*
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Table II-4 Chi-square analysis, insertion of tympanostomy tubes by plan
Plan Insertion of tubes
Yes No
HMOl 239 731 970
(187) 0^83)
HM02 368 1889 2257
(435) (1822)
HM03 164 606 770
(149) (621)
771 3226 3997
X^=32.6 df=2 p<0.05*
Table II-5Chi-square analysis, insertion of tympanostomy tubes by gender
Gender Insertion of tubes
Yes No
Male 453 1732 2185
(421) (1764)
Female 318 1494 1812
(350) (1462)
771 3226 3997
X^=6.6 df=l p<0.05*
Table II-6 Chi-square analysis, antibiotic therapy during an episode and presence of 
tympanostomy tubes
Tymp tubes Antibiotic therapy 
Yes No
Yes 786 777 1563
(1116) (447)
No 12,351 4483 16,834
(12,020) (4813)
13,137 5260 18,397
X%=373 df=l p<0.05*
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Table II-7 T-test - number of episodes during study
Severity N Mean St.Dev DF T p-value
Acute
Chronic
3032
3662
1.63
3.11
0.84
1.64
6692.0 -44.91 <0.05*
Table II-8 - number of antibiotic claims during study
Severity N Mean St.Dev DF T p-value
Acute
Chronic
3032
3662
1.61
5.45
0.89
.436
6692.0 -47.6643 <0.05*
Table II-9 - number of amoxycillin claims
Severity N Mean St.Dev DF T p-value
Acute
Chronic
3032
3662
0.93
1.23
0.75
1.11
6692 -13.0055 <0.05*
Table 11-10 - number of amoxydllin/potassium clav. claims during study
Severity N Mean St.Dev DF T p-value
Acute
Chronic
3032
3662
0.14
(163
0.39
0.87
6692.0 -28.8466 <0.05*
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11. Appendix III - statistical analyses- episodes of otitis media
Table III-l Chi-square analysis, suppurative Vs Non-suppurative otitis media 
diagnosis by treatment
Diagnosis Antibiotic treatment
Yes No
Nonsupp 1878 1464 3342
(2386) (956)
Snpp 3452 992 4444
(3173) (1271)
Unspecified 7807 2804 10,611
(7577) (3034)
13,137 5260 18,397xWgg df=2 p<0.05*
Table HI-2 - T-test, number of antibiotic claims per episode
Severity N Mean St.Dev DF T p-value
Acute 4256 1.14 0.3639 13135 -32.154 <0.05*
Chronic 8881 2.25 2.2225
Table III-3 - T-test, total drug cost per episode day
Severity N Mean StDev DF T p-value
Acute 4256 1.20 1.19 13135 -6.2827 <0.05*
Chronic 8881 1.34 1.18
Table III-4 - T-test, total cost per episode day
Severity N Mean St.Dev DF T p-value
Acute 4256 6.52 15.78 13135 -1.5505 <0.05*
Chronic 8881 6.98 15.90
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Table HI-5 - T-test, amoxycillin not used
Severity N Mean St.Dev DF T p-value
Acute 4256 0.34 0.47 13135 -16.4614 <0.05*
Chronic 8881 0.49 0.50
Table IH-6 - T-test, amoxycillin used first
Severity N Mean St.Dev DF T p-value
Acute 4256 0.65 0.48 13135 22.9417 <0.05*
Chronic 8881 0.44 0.50
Table IH-7 - T-test, amoxycillin/potassium clav. not used
Severity N Mean St. Dev DF T p-value
Acute 4256 0.90 0.30 13135 25.5189 <0.05*
Chronic 8881 0.74 0.44
Table IH-8 - T-test, amoxycillin/potassium clav. used first
Severity N Mean St,Dev DF T p-value
Acute 4256 0.09 0.28 13135 -9.3953 <0.05*
Chronic 8881 0.14 0.35
Table HI-9 - T-test, cefaclor not used
Severity N Mean St.Dev DF T p-value
Acute 4256 0.89 0.31 13135 17.7303 <0.05*
Chronic 8881 0.76 0.42
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Table HI-10 - T-test, cefaclor used first
Severity N Mean St.Dev DF T p-value
Acute
Chronic
4256
8881
0.08
0.80
0.28
0.40
13135 -9.4639 <0.05*
Table IH-11 - T-test, other cephalosporin not used
Severity N Mean StDev DF T p-value
Acute
Chronic
4256
8881
0.93
0.80
0.26
0.40
13135 19.0329 <0.05*
Table IH-12 - T-test, other cephalosporin used first
Severity N Mean StDev DF T p-value
Acute
Chronic
4256
8881
0.06
0.10
0.24
0.30
13135 -7.4882 <0.05*
Table IH-13 - T-test, any other antibiotic not used
Severity N Mean St.Dev DF T p-value
Acute
Chronic
4256
8881
0.85
0.66
0.36
0.47
13135 23.1925 <0.05*
Table IH-14 - T-test, any other antibiotic used first
Severity N Mean St,Dev DF T p-value
Acute
Chronic
4256
8881
0.12
0.17
0.32
0.38
13135 -8.1885 <0.05*
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Table III -15 stepwise logistic regression, amoxycillin as first drug in an episode
Variable coding scheme
Variable descriptor Value=0 Value=l
Chronic otitis indicator acute chronic
HMOl indicator not HMOl HMOl
Log length of episode n/a n/a
HM03 indicator not HM03 HM03
no. episodes prior to study n/a n/a
Female male female
Step Variable Chi-square
1 Chronic otitis indicator
2 HMOl indicator
3 Log length of episode
4 HM03 indicator
5 no. episodes prior to study
6 Female
p-value
506.100
346.900
54.544
42.988
44.347
5.611
<0.5*
<0.5*
<0.5*
<0.5*
<0.5*
<0.5*
Odds ratios (Amoxycillin used during first episode) 
Variable Ratio
Chronic otitis indicator
HMOl indicator
Log length of episode
HM03 indicator
no. episodes prior to study
Female
0.532
0.408
0.827
0.727
0.908
1.090
166
Table III -16 stepwise logistic regression, amoxycillin/potassium clav. as first drug in
an episode
Variable coding scheme 
Variable descriptor Value=0
Chronic otitis indicator acute
HM03 indicator not HM03
Office/outpatient visits n/a
Age at start of episoden/a 
HMOl indicator not HMOl
n/a
Value=l
chronic
HM03
n/a
HMOl
Step Variable Chi-square p-value
1 Chronic otitis indicator
2 HM03 indicator
3 Office/outpatient visits
4 Age at start of episode
5 HMOl indicator
87.6951
40.5886
12.7580
13.4133
4.0130
<0.5*
<0.5*
<0.5*
<0.5*
<0.5*
Odds ratios (Amoxycillin/potassium clav. used during first episode=l) 
Variable Ratio
Chronic otitis indicator 
HM03 indicator 
Office/outpatient visits 
Age at start of episode 
HMOl indicator
1.061
1.687
0.649
1.057
1.134
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Table in  -17 stepwise logistic regression, cefaclor, as first drug in an episode
Variable coding scheme
Variable descriptor Value=0 Value=l
HM02 indicator not HM02 HM02
Chronic otitis indicator acute chronic
Emergency visits n/a n/a
No. episodes prior to study n/a n/a
Female male female
Step Variable Chi-square p-value
1 HM02 indicator 165.8000 <0.5*
2 Chronic otitis indicator 76.8054 <0.5*
3 Emergency visits 24.5417 <0.5*
4 No. episodes prior to study 22.9201 <0.5*
5 female 5.8776 <0.5*
Odds ratios (Cefaclor used during first episode=l) 
Variable Ratio
HM02 indicator 
Chronic otitis indicator 
Emergency visits 
No. episodes prior to study 
Female
0.512
1.631
1.612
1.099
1.140
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Table 111-18 Muittest procedure - total cost analysis based on the initial antibiotic 
during an episode
Muittest coefficients
Test
Amox vs amoxXclav 
Cef vs amox/clav 
Oth ceph vs amoxXclav 
1
Oth anti vs amoxXclav
Amoxycillin
1
0
0
Amoxycillin/clav
-1
-1
-1
Cefaclor
0
1
0
Other ceph
0
0
0
Other anti 
0 
0
0 -1 0 1 0
Muittest tables
Variable Statistic 
Cost Mean 
Std dev 
N
Amoxycillin
125.7
303.1
6716
Amoxycillin/clav
215.4
397.3
1639
Cefaclor
255.5
533.5 
1604
Other ceph 
242.6 
458.2 
1149
Other anti 
198.9 
543.0 
2029
Test
Amox vs amoxXclav 
Cef vs amox/clav 
Oth ceph vs amoxXclav 
Oth anti vs amoxXclav
p-value
<0.05*
<0.05*
>0.05
>0.05
Variable Statistic 
Cost per day Mean 
Std dev 
N
Amoxycillin
5.7
15.6
6716
Amoxycillin/clav
8.1
14.4
1639
Cefaclor
9.5
21.7
1604
Other ceph 
8.8 
17.2 
1149
Other anti 
6.2 
10.3 
2029
Test
Amox vs amoxXclav 
Cef vs amox/clav 
Oth ceph vs amoxXclav 
Oth anti vs amoxXclav
p-value
<0.05*
<0.05*
<0.05*
>0.05
Variable Statistic 
Antibiotic claims Mean 
Std dev 
N
Amoxycillin
1.7
1.6
6716
Amoxycillin/clav
2.1
2.2
1639
Cefaclor
2.1
2.0
1604
Other ceph
2.1
2.0
1149
Other anti 
2.1 
2.2 
2029
Test
Amox vs amoxXclav 
Cef vs amox/clav 
Oth ceph vs amoxXclav 
Oth anti vs amoxXclav
p-value
<0.05*
>0.05
>0.05
>0.05
Variable Statistic 
Length of Mean 
episode Std dev 
N
Amoxycillin
23.8
28.2
6716
Amoxycillin/clav
31.3
35.0
1639
Cefaclor
30.2
33.4
1604
Other ceph 
32.5 
36.1 
1149
Other anti 
30.9 
35.1 
2029
Test p-value
Amox vs amoxXclav <0.05*
Cef vs amox/clav >0.05
Oth ceph vs amoxXclav 
Oth anti vs amoxXclav >0.05
>0.05
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12. Appendix IV - represcribing
Table IV - 1 represcribing after initial antibiotic
1st drug 2 h d # u g Acute OM Chronic Total
No. episodes % of 1st drug No. episodes % of 1st drug No. episodes % of 1st drug
Amox Amox 131 36.69 633 35.50 764 35.70
AmoxXclav 41 11.48 250 14.02 291 13.60
Cefaclor 66 18.49 249 13.97 315 14.72
Other ceph 28 7.84 167 9.37 195 9.11
Other 91 25.49 484 27.15 575 26.87
Total 357 100 1783 100 2140 100
Amox/clav Amox 3 4.62 82 12.63 85 11.90
AmoxXclav 33 50.77 254 39.14 287 40.20
Cefaclor 11 16.92 74 11.4 85 11.90
Other ceph 7 10.77 96 14.79 103 14.43
Other 11 16.92 143 22.03 154 21.57
Total 65 100 649 100 714 100
Cefaclor Amox 6 11.32 53 8.77 59 8.98
AmoxXclav 4 7.55 116 19.21 120 18.26
Cefaclor 21 39.62 204 33.77 225 34.25
Other ceph 5 9.43 69 11.42 74 11.26
Other 17 32.08 162 26.82 179 . 27.25
Total 53 100 604 100 657 100
Other ceph Amox 3 7.69 57 12.78 60 12.37
AmoxXclav 3 7.69 83 18.61 86 17.73
Cefaclor 5 12.82 32 7.17 37 7.63
Other ceph 16 41.03 164 36.77 180 37.11
Other 12 30.77 110 24.66 122 25.15
Total 39 100 446 100 485 100
Other Amox 13 16.05 96 12.90 109 13.21
AmoxXclav 12 14.81 108 14.52 120 14.55
Cefaclor 10 12.35 130 17.47 140 16.97
Other ceph 12 14.81 99 13.31 111 13.45
Other 34 41.98 311 41.80 345 41.82
Total 81 100 744 100 825 100
170
Table IV - 2 represcribing after initial antibiotic - same provider for first and second
antibiotic claim
1st drug 2nd drug Acute OM Chronic
OM
Total
No. episodes % of 1st drug No. episodes % of 1st drug No. episodes % of 1st drug
Amox Amox 91 42.72 390 40.04 481 40.52
AmoxXclav 20 9.39 123 12.63 143 12.05
Cefaclor 30 14.08 118 12.11 148 12.47
Other ceph 15 7.04 79 8.11 94 7.92
Other 57 26.76 264 27.10 321 27.04
Total 213 100 974 100 1187 100
Amox/clav Amox 0 0 52 12.87 52 11.50
AmoxXclav 30 62.50 179 44.31 209 46.24
Cefaclor 6 12.50 40 9.90 46 10.18
Other ceph 4 8.33 54 13.37 58 12.83
Other 8 16.67 79 19.55 87 19.25
Total 48 100 404 100 452 100
Cefaclor Amox 1 3.45 21 6.07 22 5.87
AmoxXclav 2 6.90 60 17.34 62 16.53
Cefaclor 14 48.28 142 41.04 156 41.60
Other ceph 2 6.90 34 9.83 36 9.6-
Other 10 34.48 89 25.72 99 26.40
Total 29 100 346 100 375 100
Other ceph Amox 2 6.25 32 11.59 34 11.04
AmoxXclav 2 6.25 46 16.67 48 15.58
Cefaclor 3 9.38 20 7.25 23 7.47
Other ceph 14 43.75 115 41.67 129 41.88
Other 11 34.48 63 22.83 74 24.03
Total 32 100 276 100 308 100
Other Amox 10 16.95 48 10.55 58 11.28
AmoxXclav 6 10.17 56 12.13 62 12.06
Cefaclor 7 11.86 73 16.04 80 15.56
Other ceph 10 16.95 59 12.97 69 13.42
Other 26 44.07 219 48.13 245 47.67
Total 59 100 455 100 514 100
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Table IV - 3 represcribing after initial antibiotic- different provider for first and second
antibiotic claim
1st drug 2nd drug Acute OM Chronic
OM
Total
No. episodes % of 1st drug No. episodes % of 1st drug No. episodes % of 1st drug
Amox Amox 40 27.78 243 30.04 283 29.70
AmoxXclav 21 14.58 127 15.70 148 15.53
Cefaclor 36 25.00 131 16.19 167 17.52
Other ceph 13 9.03 88 10.88 101 10.60
Other 34 23.61 220 27.19 254 26.65
Total 144 100 809 100 953 100
Amox/clav Amox 3 17.65 30 12.24 33 12.60
AmoxXclav 3 17.65 75 30.61 78 29.77
Cefaclor 5 29.41 34 13.88 39 14.89
Other ceph 3 117.65 42 17.14 45 17.18
Other 3 17.65 64 26.12 67 25.57
Total 17 100 245 100 262 100
Cefaclor Amox 5 20.83 32 12.40 37 13.12
AmoxXclav 2 8.33 56 21.71 58 20.57
Cefaclor 7 29.17 62 24.03 69 24.47
Other ceph 3 12.50 35 13.57 38 13.48
Other 7 29.17 73 28.29 80 28.37
Total 24 100 258 100 282 100
Other ceph Amox 1 14.29 25 14.71 26 14.69
AmoxXclav 1 14.29 37 21.76 38 21.47
Cefaclor 2 28.57 12 7.06 14 7.91
Other ceph 2 28.57 49 28.82 51 28.81
Other 1 14.29 47 27.65 48 27.12
Total 7 100 170 100 177 100
Other Amox 3 13.64 48 16.61 51 16.40
AmoxXclav 6 27.27 52 17.99 58 18.65
Cefaclor 3 13.64 57 19.72 60 19.29
Other ceph 2 9.09 40 13.84 42 13.50
Other 8 36.36 92 31.83 100 32.15
Total 22 100 289 100 311 100
100311
172
13. Appendix V - Costs associated with treatment of chronic otitis media by 
assignment definition
Table V-1 Costs associated with the treatment of otitis media by initiating antibiotic
All HMOs
Plan Initiating
antibiotic
Physician
outpatient
services
Emergenc
yservices
inpatient
hosp.
drugs Total costs
HMO 1 None 858 13 4 18 876
106,065 2388 18,141 141 126,835
124 184 4535 8 145
84% 2% 14% 0%
Amoxycill 587 23 1 603 603
in 72,303 2989 103 10,889 86,234
123 128 103 18 356
84% 3% 0% 13%
Amoxycill 235 7 1 235 235
in/clavula 44,656 945 1000 13,558 60,159
nate 190 135 1000 58 256
74% 2% 2% 22%
Cefaclor 208 14 0 212 212
54,152 1839 0 12,471 68^^62
260 131 0 59 323
79% 3% 0% 18%
Other 138 6 3 141 141
ceph 35,127 1117 8928 8843 54,015
255 186 2976 63 383
65% 2% 17% 16%
Any other 221 7 0 225 225
antibiotic 43,375 841 0 5558 49,774
196 120 0 25 221
87% 2% 0% 11%
Total 2247 70 9 1434 2292
355,679 10,068 28,172 51,460 445,379
158 144 3130 36 194
80% 2% 6% 12%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table V-2 Costs associated with the treatment of otitis media by initiating antibiotic
All HMOs combined
Plan Initiating
antibiotic
Physician
outpatient
Emergenc
yservices
inpatient
hosp.
drugs Total costs
HMO None 639 20 2 21 656
50,241 3564 4927 254 58^#6
79 178 2463 12 90
85% 6% 8% 0%
Amoxycill 1155 75 3 1183 1183
in 157,165 12,935 5742 30,759 206,601
136 172 1914 26 175
76% 6% 3% 15%
Amoxycill 309 22 1 309 309
in/clavula 44,837 4383 3132 18,076 70,428
nate 145 199 3132 58 228
64% 6% 4% 26%
Cefaclor 334 37 2 349 349
69,015 7713 8454 20,084 105,266
207 208 4227 57 302
66% 7% 8% 19%
Other 250 8 2 250 250
ceph 49,268 1796 5626 14,796 71,486
197 225 2813 59 286
69% 2% 8% 21%
Any other 390 24 2 396 396
antibiotic 70,599 4172 15,834 13,892 104,497
181 174 7917 35 264
68% 4% 15% 13%
Total 3077 186 12 2508 3143
441,125 34^163 43,715 97,861 617,264
143 186 3643 39 196
71% 6% 7% 16%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table V-3 Costs associated with the treatment of otitis media by initiating antibiotic
All HMOs combined
Plan Initiating 
, antibiotic
Physician
outpatient
services
Emergenc inpatient
hosp.
drugs Total costs
HMO None 625 24 1 22 649
42,131 2808 2918 173 48,030
67 117 2918 8 74
88% 6% 6% 0%
Amoxycill 1134 61 5 1147 1147
in 178,910 11,843 15,103 3^,897 244,753
158 194 3021 34 213
73% 5% 6% 16%
Amoxycill 429 21 2 434 434
in/clavula 77,648 3974 3360 28,166 113,148
nate 181 189 1680 65 261
69% 3% 3% 25%
Cefaclor 363 27 1 368 368
82^T8 6898 975 26,103 116,454
227 255 975 71 316
71% 6% 1% 22%
Other 313 12 1 315 315
ceph 62,137 1171 2598 22,834 88,740
199 98 2598 72 282
70% 1% 3% 26%
Any other 481 20 5 487 487
antibiotic 113,675 3410 10,925 20,287 148,297
236 171 2185 42 305
77% 2% 7% 14%
Total 3345 165 15 2773 3400
556,980 30,103 35,879 136,460 759,422
167 182 2392 49 223
73% 4% 5% 18%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table V-4 Costs associated with the treatment of otitis media by initiating antibiotic
All HMOs combined
Clironic Otitis VIedia - tympanostomy tubes
Plan Initiating Physician Emergenc inpatient drugs Total costs
antibiotic outpatient
services
yservices
hosp.
HMO None 74 1 1 1 76
17,228 156 ■ 6406 15 23,805
233 156 6406 15 313
72% 1% 27% 0%
Amoxycill 26 0 1 26 26
in 4991 0 3605 435 9031
192 0 3605 17 347
55% 0% 40% 5%
Amoxycill 7 0 1 8 8
in/clavula 557 0 2545 555 3657
nate 80 0 2545 69 457
15% 0% 70% 15%
Cefaclor 21 1 0 21 21
3923 80 0 971 4974
187 80 0 46 237
79% 2% 0% 19%
Other 8 0 0 8 8
ceph 2060 0 0 403 2463
257 0 0 50 308
84% 0% 0% 16%
Any other 26 1 0 27 27
antibiotic 4156 235 0 503 4894
160 235 0 19 181
85% 5% 0% 10%
Total 162 3 3 91 166
32,915 471 12,556 28M 48,824
203 157 4185 32 294
67% 1% 26% 6%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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Table V-5 Costs associated with the treatment of otitis media by initiating antibiotic
All HMOs combined
Plan Initiating
antibiotic
Physician
outpatient
services
Emergenc
yservices
inpatient
hosp.
drugs Total costs
HMO None 1059 52 1 18 1104
81,364 6802 0 162 88J28
77 131 0 9 80
92% 8% 0% 0%
Amoxycill 946 48 3 978 978
in 77,813 6229 7792 14,595 106,409
82 130 2591 15 109
73% 6% 7% 14%
Amoxycill 283 13 3 288 288
in/clavula 47,900 1955 5296 13,781 6^932
nate 169 150 1765 48 239
70% 3% 8% 20%
Cefaclor 290 17 1 0 300
44,939 2406 3733 13,795 64,932
155 142 3733 46 239
69% 4% 6% 21%
Other 173 7 0 176 176
ceph 27,753 879 0 9605 38J37
160 126 0 55 217
73% 2% 0% 25%
Any other 381 21 1 395 395
antibiotic 49,434 3183 793 10,079 63,489
130 152 793 26 161
78% 5% 1% 16%
Total 3132 158 9 2155 3241
329,203 21,454 17,593 62,017 430,267
105 136 1955 29 133
77% 5% 4% 14%
Number of members 
Amount paid (in $) 
Amount paid per member 
Percent of total costs
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